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ABSTRACT 
Reina Watanabe 
 
CONTRIBUTION OF K+ CHANNELS TO CORONARY DYSFUNCTION  
IN METABOLIC SYNDROME  
 
Coronary microvascular function is markedly impaired by the onset of the 
metabolic syndrome and may be an important contributor to the increased 
cardiovascular events associated with this mutlifactorial disorder. Despite increasing 
appreciation for the role of coronary K+ channels in regulation of coronary microvascular 
function, the contribution of K+ channels to the deleterious influence of metabolic 
syndrome has not been determined. Accordingly, the overall goal of this investigation 
was to delineate the mechanistic contribution of K+ channels to coronary microvascular 
dysfunction in metabolic syndrome. Experiments were performed on Ossabaw miniature 
swine fed a normal maintenance diet or an excess calorie atherogenic diet that induces 
the classical clinical features of metabolic syndrome including obesity, insulin resistance, 
impaired glucose tolerance, dyslipidemia, hyperleptinemia, and atherosclerosis. 
Experiments involved in vivo studies of coronary blood flow in open-chest anesthetized 
swine as well as conscious, chronically instrumented swine and in vitro studies in 
isolated coronary arteries, arterioles, and vascular smooth muscle cells. We found that 
coronary microvascular dysfunction in the metabolic syndrome significantly impairs 
coronary vasodilation in response to metabolic as well as ischemic stimuli. This 
impairment was directly related to decreased membrane trafficking and functional 
expression of BKCa channels in vascular smooth muscle cells that was accompanied by 
augmented L-type Ca2+ channel activity and increased intracellular Ca2+ concentration. 
In addition, we discovered that impairment of coronary vasodilation in the metabolic 
 v 
syndrome is mediated by reductions in the functional contribution of voltage-dependent 
K+ channels to the dilator response. Taken together, findings from this investigation 
demonstrate that the metabolic syndrome markedly attenuates coronary microvascular 
function via the diminished contribution of K+ channels to the overall control of coronary 
blood flow. Our data implicate impaired functional expression of coronary K+ channels as 
a critical mechanism underlying the increased incidence of cardiac arrhythmias, 
infarction and sudden cardiac death in obese patients with the metabolic syndrome. 
 
 
 
      Johnathan D. Tune, Ph.D., Chair 
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CHAPTER 1: INTRODUCTION 
 
The epidemic of obesity and metabolic syndrome 
Obesity in Western society has reached epidemic proportions, as an estimated 100 
million Americans are overweight or obese (66). In addition, recent estimates indicate 
that there are approximately 1 billion persons worldwide who are overweight (body mass 
index 25 – 30 kg/m2) (161). Many of these individuals are affected for years by the so 
called “metabolic syndrome,” the combined disorder of obesity, insulin resistance, 
hypertension and dyslipidemia before therapeutic measures are initiated or the 
development of overt type II diabetes mellitus occurs. Presently, an estimated 30% of 
the U.S. adult population exhibits characteristics of the pre-diabetic metabolic syndrome 
(3; 57; 116). According to the commonly used diagnostic definition of the National 
Cholesterol Education Program’s Adult Treatment Panel-III, a patient is diagnosed with 
metabolic syndrome when three or more of the following clinical criteria are present in 
one individual: elevated waist circumference (≥ 40 in for men, 35 in for women), elevated 
triglycerides (≥ 150 mg/dL), reduced HDL cholesterol (< 40 mg/dL for men, 50 mg/dl for 
women), elevated blood pressure  (≥ 130/85 mmHg), and elevated fasting glucose (≥110 
mg/dL) (101). These contribute to the cluster of metabolic risk factors including 
abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, insulin resistance 
and/or glucose intolerance, prothrombotic state, and proinflammatory state that comprise 
the syndrome (66). 
Earlier studies have established that each component of metabolic syndrome is 
an independent risk factor for cardiovascular disease (66). Recent estimates suggest 
that individuals with metabolic syndrome have a 61% increased risk of cardiovascular 
disease compared to those without metabolic syndrome (59). Follow-up data of the 1948 
Framingham Heart Study, which sought to identify common factors that contribute to 
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cardiovascular disease, demonstrated significantly increased incidence of coronary 
atherosclerotic disease, cardiomyopathies, myocardial infarction, sudden death, 
congestive heart failure, and atherothrombotic stroke in obese subjects relative to lean 
(59; 66; 70; 75; 76; 96; 129). Obese subjects were also found to be at twice the risk of 
coronary disease (75). Despite the known link between obesity and cardiovascular 
disease the pathophysiologic mechanisms underlying obesity- and metabolic syndrome-
induced cardiovascular diseases remain poorly understood. Accordingly, the long-term 
goal our research is to delineate mechanisms of obesity-related coronary vascular 
disease and thereby elucidate pathways and novel therapeutic targets to reduce the 
incidence of cardiovascular complications in this patient population. The central premise 
of our studies is that impaired coronary microvascular function is an important 
contributor to increased cardiovascular morbidity and mortality in obese patients with the 
metabolic syndrome. 
 
Metabolic syndrome and the coronary circulation 
 Due to the limited anaerobic capacity of the myocardium, the heart depends on a 
continuous supply of oxygen from the coronary circulation to meet its metabolic 
requirements (43; 151; 154). To ensure adequate balance between coronary blood flow 
and myocardial metabolism, powerful regulatory mechanisms exist to maintain nutritive 
blood flow to the heart to protect the myocardium from ischemia. If this need for oxygen 
is not met, the resulting ischemia substantially diminishes cardiac function within 
seconds (25; 68; 69; 132). Thus, under normal physiological conditions myocardial 
oxygen delivery is closely matched with the rate of myocardial oxidative metabolism.  
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There is mounting evidence that this ability to match oxygen delivery to 
myocardial demand is diminished in metabolic syndrome. Data from human patients 
demonstrate diminished coronary flow reserve (the difference between maximal and 
baseline coronary blood flow) with obesity and metabolic syndrome (27; 33; 87; 92; 137), 
indicating that the capacity to vasodilate is greatly reduced in obesity. For instance, 
Kiviniemi et al. reported a negative correlation between coronary flow reserve and waist 
to hip ratio (Figure 1.1) such that maximal flow capacity diminished in proportion to the 
degree of obesity (87). In addition to diminished flow reserve, recent investigations 
provide evidence for impaired insulin-mediated capillary recruitment, altered obesity-
related endocrine signaling, and increased arterial stiffening in metabolic syndrome (125; 
139). Remodeling of the microcirculation is considered a hallmark of established 
vascular disease, and reduced perfusion has been linked to reduced wall compliance 
and increased wall thickness in peripheral arterioles of obese Zucker rat (144). 
Therefore, microvascular defects play an important role in the end-organ damage 
associated with this combined disorder.  
 
To examine the effects of the metabolic syndrome on myocardial oxygen supply 
demand balance, our laboratory explored the control of coronary blood flow in 
conscious, instrumented control and chronically high-fat-fed dogs at rest and during 
Figure 1.1 Correlation of waist-to-hip ratio 
with coronary flow velocity reserve (CFVR; 
n = 36).  Taken from Kiviniemi et al. (73) 
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graded treadmill exercise (141). We found that the metabolic syndrome significantly 
attenuated exercise-induced coronary hyperemia. Specifically, slopes of coronary blood 
flow vs. MVO2 and coronary conductance (coronary blood flow normalized to mean aortic 
pressure) vs. MVO2 relationships were significantly reduced in metabolic syndrome dogs 
relative to lean controls (Figure 1.2A), indicating that metabolic syndrome impairs the 
ability of the coronary circulation to match myocardial oxygen delivery to metabolism. In 
addition, there was a significant parallel downward shift in the relationship between 
coronary venous oxygen tension and MVO2 (a sensitive measure of tissue oxygenation 
that reflects whether changes in coronary blood flow adequately match changes in 
MVO2) in the high-fat-fed dogs (Figure 1.2B), indicating that in these animals, oxygen 
delivery was not sufficient to meet myocardial metabolic demand such that these 
animals had to increase extraction in order to meet their requirements for oxygen. 
Further, this finding suggests a loss of a tonic vasodilator mechanism and/or activation 
of a tonic vasoconstrictor mechanism (151; 154) that was present at rest as well as 
during exercise. These data are consistent with attenuated coronary flow responses to 
Figure 1.2 Metabolic syndrome impairs the ability of the coronary circulation to 
match myocardial oxygen delivery to myocardial metabolism.  Taken from Setty 
et al. (118) 
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cardiac pacing in obese patients (27) and indicate that metabolic syndrome significantly 
impairs regulation of coronary microvascular function to the extent that the balance 
between coronary blood flow and myocardial metabolism is compromised.  
The mechanisms responsible for coronary microvascular dysfunction in 
metabolic syndrome have not been fully elucidated. Recent data from our laboratory 
indicate that coronary vasomotor dysfunction in the metabolic syndrome is related to 
sensitization of key coronary vasoconstrictor pathways (39; 88; 89; 141; 173). In 
particular, metabolic syndrome is associated with elevated basal plasma epinephrine 
and norepinephrine levels and sensitization of α1- and α2-adrenoceptor signaling in 
metabolic syndrome dogs that limits control of coronary blood flow in response to 
sympathetic activation (39). In addition, metabolic syndrome was associated with 
elevated plasma renin activity and angiotensin II levels that act via increased angiotensin 
II type 1 receptors (173). These data indicate that coronary vasomotor dysfunction in 
metabolic syndrome is related to chronic activation of the renin-angiotensin and 
sympathetic nervous system that leads to augmented AT1 and α1-adrenoceptor 
mediated coronary vasoconstriction. Further, coronary vasoconstriction in canine 
isolated arterioles to endothelin-1 was similar in control and metabolic syndrome despite 
significantly decreased ETA-receptor transcript levels and protein expression, indicating 
that ETA-receptor signaling is also sensitized by induction of metabolic syndrome (90). 
These pathways converge on smooth muscle L-type Ca2+ channels to increase 
intracellular Ca2+ concentrations and depolarize smooth muscle cells, thereby inducing 
vasoconstriction (88). In addition, the sensitization of the angiotensin signaling pathway 
directly contributes to microvascular dysfunction as inhibition of angiotensin II type 1 
(AT1) receptors significantly improved the balance between coronary blood flow and 
myocardial metabolism in dogs with the metabolic syndrome (173).  
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Several recent studies suggest that alterations in these mechanisms, especially 
angiotensin II, could directly inhibit K+ channels, in particular large conductance Ca2+-
activated (BKCa) K
+ channels. Agonist-induced vasoconstriction by angiotensin II has 
been found to involve inhibition of BKCa channels by c-Src tyrosine kinase via direct 
phosphorylation of the channel protein (4). Further, administration of angiotensin II-
activated calcineurin/NFATc3 signaling in murine arterial smooth muscle significantly 
diminished BKCa channel function via down-regulation of the BKCa channel β1 subunit 
expression (114). Consistent with these findings, patch-clamp studies of coronary 
vascular smooth muscle cells have demonstrated that angiotensin II inhibits BKCa 
channel function by altering the open and closed states of the channel thereby 
prolonging the closed confirmation (150). These findings suggest that sustained 
angiotensin II signaling, such as seen in hypertension or metabolic syndrome, impair K+ 
channel-mediated dilatory mechanisms. This can in turn be linked to depolarization of 
vascular smooth muscle membrane potential (Em) and induction of arterial dysfunction 
(4; 8; 21; 23; 88; 114; 150). These previous findings indicate that in addition to enhanced 
vasoconstrictor pathways, depressed vasodilator mechanisms could also contribute to 
impaired microvascular function in metabolic syndrome. 
 
Coronary K+ channels and metabolic syndrome 
Vascular smooth muscle cells express a variety of ion channels involved in a 
wide number of physiological and pathophysiological mechanisms. K+ channel activity is 
an important factor in the determination and regulation of membrane potential and 
vascular tone (81; 113). The opening of K+ channels in smooth muscle cells leads to 
diffusion of K+ ions out of the cell, causing membrane hyperpolarization and closure of 
voltage-gated Ca2+ channels (Figure 1.3). This in turn results in a decreased 
concentration of intracellular Ca2+ and induces vasorelaxation. The closure of K+ 
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channels has the opposite effect, leading to the opening of L-type Ca2+ channels and 
membrane depolarization, inducing an increase in intracellular Ca2+ levels, and 
ultimately resulting in vasoconstriction. Many cellular metabolites, such as endothelial- 
dependent factors (e.g. nitric oxide (NO), prostacyclin, endothelial-derived 
hyperpolarizing factors (EDHF)) as well as endogenous cardiomyocyte-derived 
metabolites (e.g. adenosine, hydrogen peroxide) are released in response to increased 
myocardial metabolism and/or decreased tissue oxygenation to induce vasodilation 
through smooth muscle K+-channel mediated pathways (82).  
Importantly, recent studies have linked metabolic syndrome with diminished 
functional expression of vascular smooth muscle K+ channels (26; 38; 73; 108). BKCa 
channels of insulin resistant rat mesenteric arterial myocytes were found to have 
reduced current density relative to lean while single channel activity and channel protein 
expression remained similar (38). In arterial myocytes of diabetic fatty rat models of type 
II diabetes mellitus, BKCa channel current was diminished despite absence of changes in 
Figure 1.3 Schematic diagram of electromechanical coupling in 
vascular smooth muscle. Taken from Jackson (68). 
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channel expression (26). Alternatively, diminished BKCa channel function could be 
related to reduced activation of the channels by factors such as prostacyclin (101). 
Further, decreased coupling of sarcoplasmic reticulum-mediated Ca2+ sparks to 
spontaneous transient outward K+ currents were demonstrated in coronary microvessels 
of alloxan-diabetic dyslipidemic swine (108). These changes are not limited to BKCa 
channels, as studies also report impaired functional dilation of KATP channels in obese 
Zucker rat models without changes in protein expression, linking impaired dilation to KATP 
channel sensitivity (73). Therefore, decreases in K+ channel function could represent an 
important component of coronary vascular dysfunction in disease states such as 
metabolic syndrome. However, despite decades of research, the contribution of K+ 
channels to the regulation of coronary blood flow has not been fully elucidated, 
especially in the setting of the metabolic syndrome.  
 
KCa channels 
There are three major classifications of K+ channels regulated by intracellular 
Ca2+ levels based according to the biophysical property of conductance (i.e. by the slope 
of their single channel current-voltage relationships): small (SKCa), intermediate (IKCa) 
and large/big (BKCa) conductance K
+ channels. Very little is known about the role of SKCa 
and IKCa channels in the regulation of coronary blood flow. No patch-clamp data are 
available regarding SKCa channels in coronary vascular smooth muscle. IKCa channels 
are expressed in cultured coronary smooth muscle cells and may contribute to 
phenotypic modulation (148), but their role in coronary vascular reactivity remains 
unknown. The few studies conducted of SKCa and IKCa channel involvement in coronary 
vasodilation seem to suggest an involvement of these channels in mediating EDHF-
induced dilation (31; 58). Smooth muscle cell function of SKCa and IKCa channels and its 
contribution to coronary blood flow will be an interesting area of future research. 
 9 
More is known about the molecular and biophysical properties of coronary 
vascular smooth muscle BKCa channels (32; 146). BKCa channels are highly expressed in 
the coronary vascular smooth muscle (20; 108; 143) and have been implicated in 
coronary endothelial-dependent dilation under normal-lean conditions (71; 105; 106). In 
particular, bradykinin-induced endothelial-dependent relaxation in coronary arteries is 
mediated, in part, by the activation of BKCa channels (71; 105; 106). Studies in swine 
implicate endothelial NO release, hydroxyl radicals, or cytochrome-P450-independent 
endothelial hyperpolarizing factors (71), whereas studies in human coronary artery do 
not support a role for NO (105). Flow-induced vasodilation of human coronary arteries 
has also been reported to involve BKCa channels but via an NO-mediated pathway that is 
lost in patients with coronary artery disease (106). Despite the evidence for BKCa 
channel contribution to endothelial-dependent dilation, earlier studies failed to show a 
significant effect of BKCa channel blockade on resting coronary blood flow, though 
evidence suggests a role in exercise-induced and ischemic vasodilation (103; 115). 
Merkus et al. found that administration of the BKCa channel inhibitor tetraethylammonium 
resulted in a significant decrease in the relationship between coronary venous PO2 and 
MVO2 (Figure 1.4A) in normal-lean swine both at rest and during exercise (103). Animal 
and human studies indicate that this relationship under control conditions is similar in 
pigs, dogs, and in humans patients (42; 50; 103; 155). In addition, Node et al. reported 
that the BKCa channel antagonist iberiotoxin significantly decreased coronary blood flow 
during ischemia (Figure 1.4B), suggesting that ischemic vasodilators may activate BKCa-
channel mediated dilation (115). Therefore, previous studies implicate BKCa channels in 
the regulation of endothelial-dependent dilation, metabolic control of coronary blood flow 
during increases in MVO2 and also during episodes of cardiac ischemia.  
 
 
 10 
 
 
 
 
 
 
 
 
Even fewer studies have examined a role for BKCa channels in obesity and 
metabolic syndrome. Interpretation of the role for BKCa channels in vascular disease is 
confounded by the presence of conflicting results among the different components of 
metabolic syndrome, as summarized in Table 1.1. Evidence for diminished BKCa channel 
function has been observed in models of insulin resistance (38) and high-fat feeding 
(168). Numerous studies investigating BKCa channel role in hypertension alone observed 
evidence for increased BKCa channel function (98-100; 174) whereas others found 
diminished function (7; 21; 23). Findings in models of overt type I and type II diabetes 
Figure 1.4 Role of BKCa channels in coronary vasodilation during 
exercise (A; Merkus et al. (84)) and myocardial ischemia (B; Node et al. 
(94)). 
Figure 1.5 Spontaneous 
transient outward currents 
(STOCS) are attenuated 
in smooth muscle cells 
from microvessels 
obtained from diabetic 
dyslipidemic animals but 
not in cells from conduit 
arteries.  Taken from 
Mokelke et al. (88) 
Control 
TEA 
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mellitus are less clear, as there is evidence for decreased BKCa channel function (102), 
no change (169), as well as increased function (109). These may be due to species, 
vascular bed examined, or artery size (108; 109). Recent data from the Sturek laboratory 
indicates that diabetic dyslipidemia increases the functional coupling of BKCa channels to 
sarcoplasmic reticulum Ca2+ release in vascular smooth muscle cells from large-conduit 
coronary arteries (108). This increase was attributed to a compensatory change in 
response to the increase in Ca2+ influx (or a vasoconstrictor influence) as previously 
noted in conduit arteries of aldosterone-salt hypertensive rats (99). However, additional 
studies in coronary microvessels revealed a significant decrease in the coupling of 
sarcoplasmic reticulum-mediated Ca2+ spark events (which activate BKCa channels) with 
spontaneous transient outward K+ current (STOC) frequency (Figure 1.5) (108). These 
findings indicate that diabetic dyslipidemia impairs microvascular BKCa channel function, 
however, the contribution of BKCa channel defects to the control of coronary blood flow 
and vascular dysfunction in metabolic syndrome has not been directly examined. 
Table 1.1. Summary of the role of BKCa channels in vascular disease. 
Investigators Species Model Vascular bed Role of BKCa channels 
Dimitropoulou 
et al. 2002 
(38) 
Rats Insulin 
resistance 
Mesenteric 
microvessels 
↓ current 
 protein expression 
 unitary conductance 
 Ca2+/voltage sensitivity 
Yang et al. 
2007 (168) 
Pig High fat diet Coronary 
artery 
↓ current 
Du et al. 2006 
(41) 
Rabbit High 
cholesterol 
diet 
Sphincter of 
Oddi 
↓ protein expression 
Godlewski et 
al. 2009 (62) 
HEK 
cells 
High 
cholesterol 
Mesenteric 
artery 
↓ current 
Jeremy-
McCarron 
2000 (83) 
Rabbit High 
cholesterol 
Femoral 
artery 
↓ dilation 
Ye et al. 2004 
(169) 
Mouse Streptozotocin 
type I 
diabetes 
mellitus 
Aorta ↓ unitary conductance 
↑ open probability 
McGahon et Rat Streptozotocin Retinal ↓ current 
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al. 2007 (102) type I 
diabetes 
mellitus 
arterioles ↓ STOCs 
↑ activation (Ca2+ sparks) 
↓ protein expression 
↓ mRNA expression 
Mokelke et al. 
2005 (108) 
Pig Alloxan-
induced 
diabetic 
dyslipidemia 
Coronary 
conduit 
arteries & 
microvessels 
↓ activation (Ca2+ sparks) 
↓ STOCs, microvessels 
 STOCs, conduit 
↓ current, microvessels 
 current, conduit 
Mokelke et al. 
2003 (109) 
Pig Alloxan-
induced 
diabetic 
dyslipidemia; 
High 
cholesterol 
Coronary 
artery 
↑ current 
 protein expression 
 
Burnham et 
al. 2006 (26) 
Rat ZDF type II 
diabetes 
mellitus 
Mesenteric 
artery 
↓ current 
 protein expression 
 mRNA expression 
Lu T et al. 
2005 (101) 
Rat ZDF type II 
diabetes 
mellitus 
Coronary 
artery 
 current 
↓ activation (PGI) 
 protein expression 
Liu et al. 1995 
(99) 
Rat Aldosterone-
salt 
hypertension 
Aorta ↑ STOCs 
 unitary conductance 
Liu et al.1997 
(100) 
Rat Spontaneous 
hypertension 
Aorta ↑ current 
↑ protein expression 
 mRNA expression 
Liu et al. 1998 
(98) 
Rat Spontaneous 
hypertension 
Cerebral 
arterioles 
↑ current 
↑ protein expression 
 unitary conductance 
 Ca2+/voltage sensitivity 
 
Zhang Y et al. 
2005 (174) 
Rat Spontaneous 
hypertension 
Mesenteric 
artery 
↑ STOCs 
↑ current 
↑ protein expression 
Amberg et al. 
2003 (7) 
Rat Ang II-
induced 
hypertension 
Cerebral 
artery 
↓ current 
↑ activation (Ca2+ sparks) 
↓ protein expression 
Bratz et al. 
2005 (23) 
Rat l-NNA-
induced 
hypertension 
Mesenteric 
artery 
↓ current 
 unitary conductance 
 Ca2+/voltage sensitivity 
Bratz et al. 
2005 (21) 
Rat l-NNA-
induced 
hypertension 
Mesenteric 
artery 
↓ protein expression 
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KV channels  
Voltage-gated, delayed rectifier K+ (KV) channels are prominently expressed in 
coronary artery smooth muscle cells (63). These channels conduct outward, 
hyperpolarizing K+ current that is important for the regulation of cell membrane potential 
(80; 126) and determining coronary vascular resistance and blood flow (131). Recent 
studies implicate KV channels as important end-effectors in the regulation of local 
metabolic control of coronary blood flow as well as in ischemic coronary vasodilation. 
More specifically, Saitoh et al. demonstrated that coronary infusion of the KV channel 
antagonist 4-aminopyridine in dogs significantly impaired the vasodilatory response to 
pacing and norepinephrine-induced increases in MVO2 (135). Importantly, they observed 
a significant difference in the slope of the relationship between coronary venous oxygen 
tension and MVO2 (Figure 1.6A), indicating a mismatch in the balance between 
myocardial oxygen delivery and myocardial metabolism with KV channel inhibition. In 
addition, Dick et al. recently found that KV channels play an important role in the 
regulation of baseline coronary blood flow and the reactive hyperemic response. This 
effect was evidenced by marked reductions in baseline coronary blood flow following 
administration of 4-aminopyridine; to the extent that myocardial ischemia was evident 
Figure 1.6 Role for KV channels in coronary vasodilation in response to 
increases in cardiac metabolism (A) and ischemia (B).  Taken from Saito et 
al. (112) and Dick et al. (33) 
 14 
(ST segment depression). In addition, 4-aminopyridine significantly decreased the 
coronary debt to repayment ratio (Figure 1.6B) thus implicating a role for KV channels in 
mediating vasodilation in response to cardiac ischemia (36). 
Despite mounting evidence for KV channel contribution in mediating local 
metabolic and ischemic vasodilation under normal physiological conditions, the effect of 
obesity and metabolic syndrome on KV channel-mediated vasodilation remains 
unknown. Recent studies have linked components of metabolic syndrome, in particular 
hypertension, to diminished KV channel current and expression in other vascular beds 
(21; 23). However, the effect of obesity and metabolic syndrome on KV channel-
mediated vasodilation warrants further investigation.  
KATP channels 
 KATP channels are comprised of pore-forming KIR6 family subunits combined with 
sulfonylurea receptor subunits. They are regulated by the ATP:ADP ratio and the 
channels close as ATP concentrations increase. The majority of evidence indicates that 
KATP channels are not obligatory for exercise-induced dilation, but rather contribute to the 
tonic regulation of coronary blood flow. In the presence of the selective KATP inhibitor 
glibenclamide, Merkus et al. found that KATP channel inhibition in a swine diminished 
coronary venous oxygen tension at any given rate of MVO2 (103). This was especially 
prominent under resting conditions and its effect diminished with increasing MVO2, which 
suggests that these channels are important for the regulation of coronary blood flow 
under baseline-resting conditions. These findings are consistent with previous data from 
our laboratory which found that KATP channel inhibition with glibenclamide in dogs 
resulted in a parallel downward shift of the relationship between coronary venous 
oxygen tension and MVO2, again indicating that KATP channels are not required for local 
metabolic coronary dilation (45; 127; 128; 156). Although one study in humans found 
that glibenclamide attenuated metabolic dilation in response to cardiac pacing (53), 
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experiments in dogs and pigs, as well as a recent study in human forearm (138), 
demonstrate only a role for tonic regulation of coronary blood flow and no role for KATP 
channels in mediating local metabolic dilation to exercise under physiological conditions. 
Alternatively, in alloxan-diabetic canines glibenclamide made the slope of the 
relationship between coronary venous oxygen tension and MVO2 more negative, 
indicating a more prominent role for KATP channels in local metabolic dilation in type I 
diabetes mellitus (156). These data suggest that KATP channel function and activity is 
possibly altered under pathophysiological conditions. However, this effect has not been 
shown in other animal models, and the contribution of KATP channels to the regulation of 
coronary blood flow and vascular tone in obesity and metabolic syndrome remains 
unexplored. 
Based on these earlier studies, we suggest that BKCa, KV, and KATP channels 
merit investigation as potential end-effectors of metabolic vasodilators. Elucidating the 
role of these important channels in the regulation of coronary blood flow, further attention 
can be focused to uncover the relative contribution of coronary K+ channels to the 
coronary vascular complications of obesity and metabolic syndrome. 
 
Hypothesis and aims of the investigation 
Earlier studies have demonstrated that coronary microvascular function is 
markedly impaired by the onset of the metabolic syndrome (27; 39; 90; 137; 141; 173) 
and indicate that this may be an important contributor to increased cardiovascular events 
in obese patients with this combined disorder (66; 70; 96). Although recent investigations 
have made important strides in elucidation of key mechanisms underlying this 
dysfunction, much remains unclear. Although there is mounting evidence of coronary K+ 
channel dysfunction in the metabolic syndrome (26; 38; 73; 108), there are no 
conclusive data to directly address the contribution of K+ channels to impaired coronary 
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microvascular responsiveness in the setting of the metabolic syndrome. Accordingly, the 
overall goal of this investigation was to delineate the mechanistic contribution of K+ 
channels to coronary microvascular dysfunction in metabolic syndrome (Figure 1.7).  
 
 
 
 
 
 
 
 
Aim 1 was designed to examine the molecular and functional expression of 
BKCa channels that regulate coronary vascular function and to elucidate 
mechanisms underlying the deleterious influence of metabolic syndrome. The 
rationale for this study came from recent investigations which found that BKCa channel 
activity was significantly impaired in coronary microvascular smooth muscle of alloxan-
diabetic dyslipidemic swine (108), mesenteric microvessels of insulin resistant rats (38), 
and coronary arterial myocytes of diabetic fatty rats (26; 101). In addition, BKCa channels 
are highly expressed in the coronary vascular smooth muscle cells (20; 108; 143) and 
have been implicated as end-effectors in the regulation of coronary vasodilation in 
response to key endothelial and metabolic metabolites (71; 105; 106). However, the 
Figure 1.7 Schematic 
diagram of proposed studies 
to examine the contribution of 
K+ channels to coronary 
microvascular dysfunction in 
metabolic syndrome. 
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contribution of BKCa channel defects to the control of coronary blood flow and vascular 
dysfunction in metabolic syndrome has not been examined. 
Aim 2 was designed to examine whether impaired functional expression of 
coronary microvascular BKCa channels in metabolic syndrome significantly 
attenuates the balance between myocardial oxygen delivery and metabolism at 
rest and during exercise-induced increases in MVO2. The rationale for this aim stems 
from studies which have shown that BKCa channels contribute to coronary endothelial-
dependent and exercise-induced dilation under normal-lean conditions (16; 103; 105; 
106). To date, no study has examined the contribution of BKCa channels to metabolic 
coronary vasodilation in the setting of the metabolic syndrome. We propose that 
decreases in BKCa channel function could be an underlying mechanism of impaired 
metabolic control of coronary blood flow in the metabolic 
Aim 3 was designed to elucidate the relative contribution of specific K+ 
channels to coronary reactive hyperemia and test the hypothesis that metabolic 
syndrome impairs coronary vasodilation to cardiac ischemia via decreases in the 
relative contribution of BKCa, KV, and KATP channels to the reactive hyperemic 
response. The rationale for this set of experiments is supported by previous 
investigations which documented a role for BKCa channels (115), KV channels (36), as 
well as KATP channels (10; 28; 172) in coronary vasodilation in response to a brief 
episode of myocardial ischemia, i.e. reactive hyperemia. However, the relative 
contribution of these specific K+ channels to ischemic coronary vasodilation has not 
been delineated in lean or obese subjects with the metabolic syndrome. 
 This study integrated molecular, cellular, and systems approaches to directly 
examine these three aims. Experiments were performed on Ossabaw miniature swine 
fed a normal maintenance diet or an excess calorie atherogenic diet that induces many 
common features of metabolic syndrome, including: obesity, insulin resistance, impaired 
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glucose tolerance, and dyslipidemia (22; 49; 145). Experiments involved in vivo studies 
of coronary blood flow in open-chest anesthetized swine as well as conscious, 
chronically instrumented swine and in vitro studies in isolated coronary arteries, 
arterioles, and vascular smooth muscle cells. Results from this investigation stand to 
offer novel mechanistic insight into the role and contribution of K+ channels in metabolic 
syndrome-induced coronary vascular disease. 
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Abstract 
The role of large conductance Ca2+-activated K+ (BKCa) channels in regulation of 
coronary microvascular function is widely appreciated, but the molecular and functional 
expression underlying the deleterious influence of metabolic syndrome has not been 
determined. Studies were conducted in Ossabaw miniature swine fed a normal 
maintenance diet (11% kcal from fat) or an excess calorie atherogenic diet (45% kcal 
from fat, 2% cholesterol, 20% kcal from fructose) that induces metabolic syndrome. 
Metabolic syndrome significantly impaired BKCa channel-mediated coronary vasodilation 
to NS1619 in vivo (30 – 100 µg) and the contribution of these channels to adenosine-
mediated microvascular vasodilation in vitro (1 – 100 µM). Metabolic syndrome reduced 
whole-cell penitrem A (1 µM) sensitive K+ current and NS1619-activated (10 µM) current 
in isolated coronary vascular smooth muscle cells. These changes were associated with 
marked increases in coronary vasoconstriction to the L-type Ca2+ channel agonist BayK 
8644 (1 pM – 10 nM) and intracellular Ca2+ concentration. BKCa channel α and β1 
subunit expression was increased in coronary arteries from metabolic syndrome swine; 
however, fewer channels were present in the plasma membrane, as confocal imaging 
revealed diffuse intracellular localization in coronary smooth muscle cells of metabolic 
syndrome swine. Coronary vascular dysfunction in metabolic syndrome is related to 
decreased membrane trafficking and functional expression of BKCa channels that is 
accompanied by significant increases in L-type Ca2+ channel-mediated coronary 
vasoconstriction and increased intracellular Ca2+ concentration.  
 
Keywords: blood flow, circulation, ion channels, obesity 
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Introduction 
Obesity is associated with cardiovascular and metabolic risk factors such as 
insulin resistance, impaired glucose tolerance, hypertension, and dyslipidemia, i.e., 
metabolic syndrome (59; 96). As each component of metabolic syndrome is an 
independent risk factor for cardiovascular disease, it is not surprising that metabolic 
syndrome patients have elevated morbidity and mortality to many cardiovascular-related 
diseases, including stroke, coronary artery disease, cardiomyopathies, myocardial 
infarction, congestive heart failure, and sudden cardiac death (66; 70; 96). However, the 
mechanisms underlying metabolic syndrome-induced cardiovascular disease remain 
poorly understood.  
Evidence suggests that coronary microvascular dysfunction may be an important 
contributor to the increased cardiovascular events associated with metabolic syndrome 
(88; 139). Recent investigations provide evidence for impaired insulin-mediated capillary 
recruitment, altered obesity-related endocrine signaling, increased arterial stiffening, and 
diminished flow reserve in metabolic syndrome (125; 139). These microvascular defects 
may play an important role in the end-organ damage associated with this combined 
disorder. Importantly, metabolic syndrome is characterized by an imbalance between 
coronary blood flow and myocardial metabolism that is related to sensitization of 
angiotensin II, endothelin-1, and α-adrenoceptor mediated vasoconstriction pathways 
(88). Alterations in these mechanisms could significantly inhibit large-conductance Ca2+-
activated K+ (BKCa) channels (4; 114; 150). BKCa channels are highly expressed in the 
coronary vascular smooth muscle (20; 108; 143) and have been implicated in exercise- 
and ischemia-induced coronary vasodilation in lean/control animals (20; 108; 115). In 
addition, BKCa channel activity was recently shown to be significantly impaired in 
coronary microvascular smooth muscle of alloxan-diabetic dyslipidemic swine (108), 
mesenteric microvessels of insulin resistant rats (38) and coronary arterial myocytes of 
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diabetic fatty rats (26; 101). A lesser studied mechanism of BKCa channel regulation is 
the trafficking of channels from intracellular membranes to the plasma membrane to 
yield functional ion channel activity. Excellent evidence exists in overexpression systems 
in cultured cells (149) but there are no reports of this novel BKCa channel trafficking 
mechanism in native vascular smooth muscle cells from in vivo models of vascular 
disease. Thus, the contribution of BKCa channel defects to the control of coronary blood 
flow and vascular dysfunction in metabolic syndrome has not been examined.  
The goal of this investigation was to examine the molecular and functional 
expression of BKCa channels that regulate coronary microvascular function and to 
elucidate mechanisms underlying the deleterious influence of metabolic syndrome. 
Studies were conducted in Ossabaw miniature swine fed a normal maintenance diet or 
an excess calorie atherogenic diet that induces many common features of metabolic 
syndrome, including: obesity, insulin resistance, impaired glucose tolerance, and 
dyslipidemia (22; 49; 145). Experiments involved in vivo studies of coronary blood flow in 
open-chest anesthetized swine and in vitro studies in isolated coronary arteries, 
arterioles, and vascular smooth muscle cells. 
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Methods 
Swine Model of Metabolic Syndrome  
All procedures were approved by the Institutional Animal Care and Use Committee in 
accordance with the Guide for the Care and Use of Laboratory Animals. Lean swine 
were fed ~2200 kcal/day of standard chow (5L80, Purina TestDiet, Richmond, IN) 
containing 18% kcal from protein, 71% kcal from complex carbohydrates, and 11% kcal 
from fat. Metabolic syndrome swine were fed an excess ~8000 kcal/day high 
fat/fructose, atherogenic diet containing 17% kcal from protein, 20% kcal from complex 
carbohydrates, 20% kcal from fructose, and 43% kcal from fat (lard and hydrogenated 
soybean and coconut oils), and supplemented with 2.0% cholesterol and 0.7% sodium 
cholate by weight (5B4L, Purina TestDiet, Richmond, IN). Prior to sacrifice, blood was 
drawn for glucose, insulin, and lipid assays (22; 49; 145) and in vivo studies were 
conducted. Pigs were then euthanized and tissue was harvested for subsequent in vitro 
analyses.  
 
Surgical Preparation and In Vivo Coronary Dose-Response Experiments  
Lean (n = 6) and metabolic syndrome (n = 5) Ossabaw swine were sedated with telazol 
(5 mg/kg, sc) and xylazine (2.2 mg/kg, sc). Animals were intubated and ventilated with 
O2-supplemented air. Anesthesia was maintained with morphine sulfate (3 mg/kg, im) 
and α-chloralose (100 mg/kg, iv). The left anterior descending coronary artery (LAD) was 
isolated and a perivascular Transonics flow transducer (2.5 mm) was placed around the 
artery. A 24 gauge angiocatheter was inserted into the LAD for infusion of the BKCa 
channel agonist NS1619 (3 – 100 µg bolus) before and after inhibition of BKCa channels 
with penitrem A (10 µg/kg, iv, Biomol). In a separate experiment (n = 4), endothelial-
dependent coronary flow reserve was assessed by intracoronary infusion of bradykinin 
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(30 µg/min) before and after penitrem A. Following in vivo experiments, hearts were 
electrically fibrillated, excised, and immediately immersed in 4°C saline to dissect tissues 
for in vitro and molecular experiments. 
 
Isolation and Functional Assessment of Coronary Arterioles  
Subepicardial coronary arterioles (50 – 150 µm in diameter) were isolated, cannulated, 
and pressurized to 60 cmH2O as previously described (89). Intraluminal diameter was 
measured continuously with videomicrometers and recorded on a MacLab workstation. 
Arterioles that were free from leaks were allowed to equilibrate for approximately 1 hr at 
37°C with the bathing physiological salt solution (PSS) solution changed every fifteen 
minutes. Coronary arterioles (Lean n = 6; Metabolic syndrome n = 5) were pre-
constricted to 50 – 70% tone with endothelin-1 (2 nM) then washed, and dose-response 
studies conducted with the stable adenosine analog 2-chloroadenosine (2-CADO; 0.1 
nM – 0.1 mM) before and after inhibition of BKCa channels with iberiotoxin (100 nM; 30 
min incubation). 
 
Functional Assessment of Isolated Epicardial Coronary Artery Rings  
Isolated coronary artery studies were performed as previously described (22; 89). Left 
circumflex coronary arteries from lean (n = 4) and metabolic syndrome (n = 4) swine 
were isolated, cleaned of surrounding tissue and cut into 3 mm ring segments. Arterial 
rings were then mounted in organ baths and optimal length was determined by 
assessing contraction to 60 mM KCl. Arterial contractile responses to L-type Ca2+ 
channel activation were assessed by the addition of graded concentrations of BayK 
8644 (0.1 pM – 10 nM).  
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Smooth Muscle Cell Isolation and Electrophysiology Studies  
Coronary vascular smooth muscle cells were isolated as previously described (22; 36). 
Patch-clamp recordings and immunocytochemistry/confocal studies (see below) were 
performed within 8 h of cell dispersion. Whole cell K+ currents were measured at room 
temperature using the conventional dialyzed configuration of the patch-clamp technique 
(36). Bath solution contained (in mM) 138 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 glucose, 10 
HEPES, and 5 Tris (pH 7.4). Pipettes had tip resistances of 2 – 4 MΩ when filled with 
solution containing (in mM) 140 KCl, 3 Mg-ATP, 0.1 Na-GTP, 0.1 EGTA, 10 HEPES, and 
5 Tris (pH 7.1). After whole-cell access was established, series resistance and 
membrane capacitance were compensated. Current-voltage relationships were 
assessed by 400-ms step pulses from -100 to +100 mV in 10-mV increments from -80 
mV holding potential. Currents were measured in the absence and presence the BKCa 
channel agonist NS1619 (10 µM) as well as with and without the BKCa channel 
antagonist penitrem A (1 µM). 
 
Fura-2 Microfluorometry 
Experiments to assess intracellular Ca2+ concentration were performed at room 
temperature using an InCyt Basic IM Calcium Imaging System (Intracellular Imaging, 
Cincinnati, OH) as previously described (22). Briefly, freshly dispersed cells were 
incubated with 2.5 mM fura-2 AM (Molecular Probes) in a shaking water bath at 37°C for 
20 min. Cells were spun down and washed in a solution containing horse serum in order 
to cleave extracellular dye. An aliquot of fura 2-loaded cells was placed on a coverslip in 
a superfusion chamber mounted atop an inverted epifluorescence microscope. Light 
from a 300-W xenon arc lamp was passed through 360 ± 10- and 380 ± 10-nm band-
pass filters. Emitted light (510 nm) was collected using a monochrome charge-coupled 
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device camera (COHU) attached to a 100-MHz Pentium data acquisition computer. Data 
are presented as F360/F380 ratio which is indicative of intracellular Ca2+ concentration. 
 
Western Blot Analysis  
Western blotting was performed as previously described (22; 39). Coronary arteries from 
lean (n = 3) and Metabolic syndrome (n = 3) swine were isolated and immediately placed 
in liquid N2 and stored at -80°C. Arteries were homogenized, centrifuged, and the 
supernatants containing total membrane protein were collected for analysis. Equivalent 
amounts of protein were loaded onto 12% (for BKCa channel α subunit, ~110 kDa) and 
7% (for BKCa channel β1 subunit, ~28 kDa) acrylamide gels for electrophoresis and 
blotting. After membranes were blocked for 1 h at ambient temperature with 5% nonfat 
milk, membranes were incubated overnight at 4°C with polyclonal antibodies directed 
against BKCa α subunit or BKCa β1 subunits (both 1:1000 dilution; Affinity BioReagents). 
Blots were washed and incubated with donkey anti-rabbit IgG-HRP secondary antibody 
(1:5000 dilution; Santa Cruz Biotechnology) for 2 h at ambient temperature. The same 
blots were stripped and reblotted with β-actin antiserum (1:3000 dilution; Santa Cruz 
Biotechnology) as the internal control. Immunoreactivity was visualized using an ECL 
Western blotting detection kit and quantified by scanning densitometry. 
 
Confocal Microscopy 
Confocal microscopy was performed similar to that previously described (85). Cells were 
fixed for 10 min in 4% paraformaldehyde/PBS. Cells were washed in PBS, 
permeabilized in 0.2% Triton X-100/PBS for 10 min, rinsed again and incubated 
overnight at 4°C in 2.5% BSA in PBS to block non-specific binding. Cells were next 
incubated for 1 h at 37°C with polyclonal antibodies directed against BKCa α (diluted 
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1:100 in 2.5% BSA in PBS; Affinity BioReagents) and/or BKCa β1 subunits (diluted 1:100 
in 2.5% BSA in PBS; Santa Cruz Biotechnology). The primary antibodies were detected 
by incubating cells for 45 min with affinity-purified IgG conjugated to Cy5 or FITC 
(Jackson ImmunoResearch) at 1:200 dilution. After final washes, the cells were mounted 
with fluoromount-G (Southern Biotechnology) and examined by laser scanning confocal 
microscopy (Zeiss). For detection of Cy5 and FITC fluorescence, the excitation was at 
488 nm and emission at 620 – 680 nm and 505 – 570 nm, respectively. Metamorph 
software was used for analysis. Staining at the periphery of the cell was compared to 
that of the cytoplasmic portion to obtain a plasma membrane/cytoplasm ratio. The ratios 
of 7 – 10 randomly chosen cells from each lean (n = 9) and Metabolic syndrome (n = 7) 
pig were averaged and corrected to background. 
 
Statistical Analyses 
Data are presented as mean ± SE and n represents number of subjects. Statistical 
comparisons were made with unpaired and paired t-tests and one- or two-way repeated 
measures analysis of variance (ANOVA) as appropriate. In all statistical tests, P < 0.05 
was considered statistically significant. When significance was found with ANOVA, a 
Student-Newman-Keuls multiple comparison test was performed to identify differences 
between treatment levels.  
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Results 
Phenotype of Ossabaw Swine  
Phenotypic characteristics of lean and metabolic syndrome are listed in Table 2.1. 
Compared to their lean counterparts, metabolic syndrome swine exhibited a 33% 
increase in body mass, 75% increase in fasting glucose, 210% increase in fasting 
insulin, 483% increase in total cholesterol, 313% increase in LDL/HDL ratio, and 105% 
increase in triglyceride levels. Using the homeostatic model assessment method, 
percent β cell function and percent insulin sensitivity diminished from 218.1% and 84.9% 
in lean swine to 158.3% and 24.5% respectively in swine with metabolic syndrome. 
Meanwhile, insulin resistance increased from 1.2 in lean to 4.1 in metabolic syndrome 
swine. 
  
 Lean 
Metabolic 
syndrome 
Body Weight (kg) 45 ± 4 60 ± 6* 
Heart wt. / Body wt. * 100 0.38 ± 0.03 0.37 ± 0.03 
Fasting glucose (mg/dl) 65 ± 5 114 ± 8* 
Fasting insulin (µU/ml) 10 ± 1 31 ± 4* 
Total cholesterol (mg/dl) 60 ± 3 350 ± 31* 
LDL/HDL ratio 0.8 ± 0.1 3.3 ± 0.3* 
Triglycerides (mg/dl) 22 ± 1 45 ± 7* 
Mean arterial pressure (mmHg) 95 ± 5 87 ± 6 
Heart rate (beats/min) 95 ± 11 108 ± 6 
 
 
 
Table 2.1 Phenotypic Characteristics of Lean and Metabolic Syndrome 
Ossabaw Swine 
Values are mean ± SE for lean (n = 15) and metabolic syndrome (n = 
13) swine. * P<0.05 vs lean. 
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Contribution of BKCa Channels to Coronary Microvascular Vasodilation  
Coronary arteriolar endothelium-independent vasodilation in vitro to 2-CADO (0.1 nM – 
0.1 mM), a stable adenosine analog was similar between lean and metabolic syndrome 
swine (Figure 2.1). However, iberiotoxin (100 nM) diminished relaxation to 2-CADO in 
arterioles from lean swine (1 µM – 100 µM; P < 0.01) but had no effect on 2-CADO-
induced relaxation in arterioles from metabolic syndrome swine (Figure 2.1). In addition, 
endothelial-dependent vasodilation to bradykinin (30 µg/min) was significantly decreased 
from 1.6 ± 0.3 ml/min/g to 1.0 ± 0.3 ml/min/g by inhibition of BKCa channels with penitrem 
A (10 µg/kg, iv) in vivo in lean swine (P = 0.01). 
 
Effect of Metabolic Syndrome on Coronary BKCa Channels In Vivo and In Vitro  
Figure 2.2 shows the coronary blood flow response to the BKCa channel agonist NS1619 
in lean and metabolic syndrome swine. NS1619 dose-dependently increased coronary 
blood flow in lean swine. However, coronary vasodilation to NS1619 was significantly 
Figure 2.1 Concentration-response curves of isolated pressurized coronary arterioles 
from lean and metabolic syndrome swine to adenosine analog 2-CADO with and 
without BKCa channel blockade by iberiotoxin (IBTX; 100 nM). Relaxation to 2-CADO 
was not different between lean (A, n = 6) and metabolic syndrome (B, n = 5) swine 
under control conditions. However, iberiotoxin diminished relaxation to 2-CADO in 
lean swine (* P < 0.01 vs control) but not in metabolic syndrome. 
 30 
attenuated in metabolic syndrome swine at 30 – 100µg (P < 0.01). NS1619 vehicle 
(ethanol) had no effect on coronary blood flow (data not shown). The decrease of 
NS1619-mediated dilation in metabolic syndrome swine was similar to that observed in 
lean swine following blockade of BKCa channels with penitrem A (Figure 2.2).  
 
Average normalized whole cell steady-state K+ current was attenuated ~20% in 
Metabolic syndrome swine (n = 7) vs. lean (n = 6) at potentials > +50 mV, i.e. currents 
biophysically consistent with BKCa channels (P < 0.05). Outward current generated in 
response to the BKCa channel agonist NS1619 (10 µM) was markedly depressed in 
coronary vascular smooth muscle cells from metabolic syndrome swine (Figure 2.3A; P 
< 0.001). Further, Penitrem A (1 µM) significantly attenuated outward K+ current at 
potentials > +50mV and abolished the difference in outward current between lean and 
metabolic syndrome swine (Figure 2.3A; P < 0.001). Vasoconstriction to the L-type Ca2+ 
channel agonist BayK 8644 was significantly elevated (1 pM – 10 nM; P < 0.01) in 
isolated coronary conduit arteries from metabolic syndrome relative to lean swine 
(Figure 2.3B). These data are consistent with findings from fura-2 studies that showed a 
Figure 2.2 BKCa channel agonist 
NS1619 produced dose-dependent 
increases in coronary blood flow that 
were attenuated in metabolic syndrome 
swine (n = 4) relative to lean (n = 5). 
Blockade of BKCa channels with 
penitrem A (10 µg/kg, iv) decreased 
NS1619-induced vasodilation in lean 
swine to a similar level as observed in 
swine with metabolic syndrome. * P < 
0.01 vs. lean at same dose. 
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significant increase in intracellular Ca2+ concentrations in metabolic syndrome 
(F360/F380 ratio = 2.97 ± 0.04) vs. lean (F360/F380 ratio = 1.36 ± 0.04) swine. 
 
Coronary BKCa Channel Protein Expression and Membrane Trafficking  
Paradoxically, Western blot analysis revealed a dramatic up-regulation in the coronary 
expression of the BKCa channels in metabolic syndrome swine as expression of the 
pore-forming α and regulatory β1 subunits were increased 57 ± 13% and 74 ± 15% (P < 
0.05), respectively (Figure 2.4). However, confocal microscopy revealed distinctly 
different patterns of BKCa channel localization in coronary vascular smooth muscle cells 
from lean and metabolic syndrome swine. BKCa channel α and β1 subunit expression 
was largely confined to the plasma membrane region in lean swine. In contrast, the BKCa 
channel subunit expression in metabolic syndrome swine was detected diffusely 
throughout the cytoplasm (Figure 2.5A). Quantitative analysis of confocal images 
Figure 2.3 A: Whole cell patch-clamp recordings demonstrated reduced current in 
coronary artery smooth muscle cells from metabolic syndrome (closed symbols, n = 
7) relative to lean swine (open symbols, n = 6). This difference was abolished and 
current was significantly attenuated in the presence of penitrem A (0.1 µM). Activation 
of BKCa channel current with NS1619 (1 µM) was significantly diminished in metabolic 
syndrome swine. B: Concentration-response studies in isometric arterial rings 
demonstrated vasoconstriction to the L-type Ca2+ channel agonist BayK 8644 was 
significantly elevated in coronary arteries from metabolic syndrome (n = 4) vs. lean 
swine (n = 4). * P < 0.01 vs. lean control at same dose.  
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revealed a ~67% reduction (P < 0.001) in the membrane/cytoplasm ratio for both α and 
β1 subunits in metabolic syndrome vs. lean smooth muscle cells (Figure 2.5B). 
 
 
 
 
 
 
 
 
   
Figure 2.4 A: Western blot analysis of BKCa channel α and β1 subunits in lean 
and metabolic syndrome swine.  B:  Averaged data demonstrating a significant 
increase in expression of both BKCa channel α and β1 subunits in metabolic 
syndrome (n = 3) relative to lean (n = 3) swine.  * P < 0.05 vs lean. 
 
A       B 
Figure 2.5 A:  Representative confocal images of BKCa channel α and β1 subunit 
expression in coronary vascular smooth muscle cells from lean and metabolic 
syndrome swine.  B:  Averaged data demonstrating metabolic syndrome significantly 
attenuated membrane expression of both BKCa channel α and β1 subunits. * P < 
0.001 vs. lean. 
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Discussion 
The present investigation was designed to examine the molecular and functional 
expression of BKCa channels and elucidate the mechanisms underlying the deleterious 
influence of metabolic syndrome. The primary findings of this study are: 1) BKCa 
channels contribute to adenosine-and bradykinin-induced coronary vasodilation in lean 
swine; 2) Metabolic syndrome significantly impairs BKCa channel-mediated coronary 
vasodilation in vivo and the contribution of these channels to adenosine-mediated 
microvascular vasodilation in vitro; 3) coronary smooth muscle BKCa channel current is 
diminished in metabolic syndrome; 4) Impaired coronary BKCa channel current in 
metabolic syndrome is associated with augmented L-type Ca2+ channel-mediated 
vasoconstriction and an increase in intracellular Ca2+ concentration; 5) Coronary 
expression of the pore-forming BKCa channel α-subunit and modulatory β1-subunit are 
up-regulated in Metabolic syndrome; but 6) membrane trafficking of BKCa channel 
subunits is defective in metabolic syndrome. Taken together, these data indicate that 
coronary vascular dysfunction in metabolic syndrome (88) is related, at least in part, to 
diminished functional expression of vascular smooth muscle BKCa channels. Further, this 
is the first report of impaired membrane trafficking of BKCa channels associated with 
coronary vascular dysfunction. 
BKCa channels are abundantly expressed in coronary vascular smooth muscle 
cells (20; 108) and data from this study demonstrate that these channels play a 
functional role in mediating endothelium-independent coronary vasodilation to the 
adenosine analog 2-CADO (Figure 2.1) and the endothelium-dependent vasodilator 
bradykinin. Our findings are consistent with earlier studies which documented that KCa 
channels contribute to endothelial-dependent relaxation (71; 105; 106; 115), exercise-
mediated dilation (103) and ischemic dilation in response to brief coronary artery 
occlusions (115). Therefore, decreases in coronary BKCa channel function could be 
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detrimental to the regulation of coronary microvascular function under a variety of 
physiologic/pathophysiologic stimuli.  
Findings from this investigation indicate coronary vascular smooth muscle BKCa 
channel function is markedly depressed by metabolic syndrome. Diminished BKCa 
channel function is evidenced by the impaired contribution of BKCa channels to 2-CADO-
mediated coronary arteriolar dilation in coronary arterioles from metabolic syndrome 
swine (Figure 2.1) and the reduction in BKCa channel current in isolated coronary 
vascular smooth muscle cells from metabolic syndrome swine (Figure 2.3). Since we did 
not repeat this experiment in denuded arterioles, it is not possible to state with certainty 
that this is a smooth muscle effect, especially since studies have demonstrated 
endothelium-dependent adenosine-induced relaxation (1; 93) in addition to its 
endothelium-independent effects. This observed impairment is consistent with other 
studies which found decreased vascular BKCa channel current in insulin resistant (38) 
and diabetic fatty rats (26; 101). Decreases in coronary total K+ current and spontaneous 
transient outward K+ currents, which are elicited by Ca2+ sparks and indicative of BKCa 
channel activation (123; 175), have also been observed in dyslipidemic (168) and 
diabetic-dyslipidemic Yucatan swine (108). Importantly, our data demonstrate that this 
decrease in coronary vascular smooth muscle BKCa channel function is phenotypically 
evident in vivo by the significant decrease in coronary vasodilation to NS1619 in open-
chest anesthetized metabolic syndrome swine (Figure 2.2). Although also used in 
cultured endothelial cell lines, recent data from Feng et al indicates that NS1619 is 
largely smooth muscle-mediated, as endothelial denudation had no effect on NS1619-
induced relaxation of human atrial microvessels (56). Additionally, we found that 
coronary vasoconstriction to L-type Ca2+ channel activation was markedly elevated in 
metabolic syndrome swine (Figure 2.3B) which is consistent with earlier data from our 
laboratory documenting increased functional expression of L-type Ca2+ channels in dogs 
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with metabolic syndrome (88). These changes in coronary electromechanical coupling 
were accompanied by significant increases in intracellular Ca2+ concentration in coronary 
smooth muscle cells from metabolic syndrome swine. The increased functional 
expression of L-type Ca2+ channels in coronary smooth muscle in vivo in metabolic 
syndrome Ossabaw swine is opposite of that in hyperlipidemia (18) and the combination 
of gross hyperglycemia and hyperlipidemia (diabetic dyslipidemia) (160). Collectively, 
these data strongly suggest that the entire metabolic syndrome milieu is critical in 
determining ion channel functional expression and results cannot be over-generalized 
from one disease state to another. 
The mechanisms underlying impaired functional expression of vascular BKCa 
channels in metabolic syndrome could be related to modifications in BKCa channel 
protein expression and/or membrane trafficking (102; 114) as well as alterations in 
channel activation kinetics and open probability (169). In experiments to address these 
possible mechanisms we found a paradoxical increase in the expression of both the 
pore-forming α-subunit and the modulatory β1- subunit in coronary arteries from 
metabolic syndrome swine (Figure 2.4). While our data are consistent with other 
investigations that have reported diminished current and channel activity in the presence 
of cardiovascular risk factor (26; 38; 101; 108; 114), they are at odds with other studies 
which documented a downregulation of either one or both BKCa channel subunits (41; 
102). However, it is important to recognize that ours is not the first example of a situation 
where BKCa channel function and protein expression are inversely related. For example, 
Benkusky et al. found that functional and molecular expression of BKCa channels in 
myometrial smooth muscle cells is regulated by gestation in a similar opposing manner 
such that BKCa current decreases while BKCa channel protein expression increases (12). 
Additionally, in collaboration with the Toro laboratory our group showed that increased 
BKCa channel current in conduit coronary arteries in lean hyperlipidemic and diabetic 
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dyslipidemic pigs is accompanied by no change in BKCa channel protein expression 
(109). We hypothesize that the increase in BKCa channel expression represents a 
compensatory increase in response to the impaired membrane trafficking of BKCa 
channel subunits in metabolic syndrome (Figure 2.5). Whether this diminished 
membrane trafficking is mediated by alternative mRNA splicing (165; 166) and/or the 
formation of channels with accessory subunits that inhibit membrane expression (164) 
merits further study.  
Another possible explanation is improper folding of proteins in the endoplasmic 
reticulum (ER) and subsequent entrapment therein due to ER stress. The ER is a central 
organelle and is the site for protein folding and maturation. Plasma membrane proteins, 
such as BKCa channels, are folded into their tertiary and quaternary structure in the ER, 
and conditions that interfere with the function of the ER, i.e. ER stress, can be 
detrimental to signal transduction and homeostatis functions of a cell. ER stress can be 
caused by the accumulation of unfolded/malfolded protein aggregates or excessive 
protein traffic and can result in decreased rate of protein translation (67). This can be 
crudely tested by incubating isolated smooth muscle cells of metabolic syndrome swine 
with chemical or pharmacological chaperones (such as 10% glycerol) which can rescue 
intracellularly-trapped proteins via protein stabilization and examining whether cell 
surface expression of BKCa channels is restored. Accumulating evidence suggests that 
ER stress may play a role in the pathogenesis of diabetes mellitus, contributing to 
pancreatic β-cell loss and insulin resistance (52) and may also link obesity and insulin 
resistance in type II diabetes mellitus (112; 121). Recent studies have identified ER 
stress as a plausible mechanism in the pathogenesis of type I diabetes mellitus (120) 
and progressive decrease in β-cell mass (120; 157). Further, chronic ER stress has also 
been found to cause a disruption of Ca2+ release (74) and similar findings have been 
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observed in the sarcoplasmic reticulum (SR), in particular upregulation of genes 
encoding SR Ca2+-handling proteins (72; 77). Whether ER stress presents in prediabetic 
metabolic syndrome and whether they contribute to the impaired trafficking of vascular 
smooth muscle cell BKCa channels would be an interesting area of further investigation. 
In summary, findings from this investigation support the hypothesis that coronary 
vascular dysfunction in metabolic syndrome is related to decreased membrane 
trafficking and functional expression of BKCa channels in vascular smooth muscle cells 
that is accompanied by significant increases in L-type Ca2+ channel-mediated coronary 
vasoconstriction and increased intracellular Ca2+ concentration (88). We propose that 
these alterations in electromechanical coupling contribute to coronary endothelial 
dysfunction (15; 29; 60; 124), sensitization of key vasoconstrictor pathways (39; 90; 173) 
and diminished functional hyperemia (27; 141) typically observed in obese subjects with 
metabolic syndrome. 
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Abstract 
This investigation was designed to examine the hypothesis that impaired 
functional expression of coronary microvascular BKCa channels in metabolic syndrome 
significantly attenuates the balance between myocardial oxygen delivery and 
metabolism at rest and during exercise-induced increases in myocardial oxygen 
consumption (MVO2). Studies were conducted in conscious, chronically instrumented 
Ossabaw swine fed a normal maintenance diet (11% kcal from fat) or an excess calorie 
atherogenic diet (45% kcal from fat, 2% cholesterol, 20% kcal from fructose) that 
induces many common features of metabolic syndrome. Data were collected under 
baseline/resting conditions and during graded treadmill exercise before and after 
blockade of BKCa channels with penitrem A (10 µg/kg, iv). We found that the exercise-
induced increases in blood pressure were significantly elevated in metabolic syndrome 
swine. No differences in heart rate were noted. Induction of metabolic syndrome 
produced a parallel downward shift in the relationship between coronary venous PO2 and 
MVO2 (P < 0.001) that was accompanied by a marked release of lactate (negative lactate 
uptake) as MVO2 was increased with exercise (P < 0.005). Inhibition of BKCa channels 
with penitrem A did not significantly affect blood pressure, heart rate, or the relationship 
between coronary venous PO2 and MVO2 in lean or metabolic syndrome swine. These 
data indicate that BKCa channels are not required for local metabolic control of coronary 
blood flow under physiological (lean) or pathophysiological (metabolic syndrome) 
conditions. Therefore, diminished functional expression of BKCa channels does not 
contribute to the impairment of myocardial oxygen-supply demand balance in metabolic 
syndrome. 
 
Keywords: coronary blood flow, myocardial oxygen consumption, exercise, penitrem A 
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Introduction 
Due to the limited anaerobic capacity of the myocardium, the heart depends on a 
continuous supply of oxygen from the coronary circulation to meet its metabolic 
requirements (151). Thus, under normal physiological conditions myocardial oxygen 
delivery is closely matched with the rate of myocardial oxidative metabolism. To ensure 
adequate balance between coronary blood flow and myocardial metabolism, powerful 
regulatory mechanisms exist to increase nutritive blood flow to the heart whenever 
myocardial oxygen consumption (MVO2) is elevated (43; 151). However, despite 
decades of research, the exact mechanisms responsible for local metabolic control of 
coronary blood flow have yet to be clearly defined (151). 
Previous studies have demonstrated that disease states such as obesity and 
metabolic syndrome significantly impair control of coronary blood flow at rest and during 
increases in MVO2 (27; 39; 90; 137; 141; 173). Coronary dysfunction in the metabolic 
syndrome is characterized by an imbalance between coronary blood flow and 
myocardial metabolism (141) which has been attributed to sensitization of key 
vasoconstrictor pathways such as angiotensin II and α1-adrenoceptors (88). Recently, 
data from our laboratory, as well as others, also established that obesity, insulin 
resistance and type II diabetes mellitus diminishes end-effector mechanisms that 
regulate coronary vasodilation (16; 26; 38; 101; 108). In particular, we found that the 
functional expression of coronary large conductance Ca2+ activated K+ channels (BKCa) 
channels is markedly depressed in Ossabaw swine with metabolic syndrome (16; 108). 
Since BKCa channels have been shown to contribute to coronary endothelial-dependent 
and exercise-induced dilation under normal-lean conditions (16; 20; 71; 103; 105; 106; 
108), we propose that decreases in BKCa channel function could be an underlying 
mechanism of impaired metabolic control of coronary blood flow in metabolic syndrome. 
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However, no study has examined the contribution of BKCa channels to metabolic 
coronary vasodilation in the setting of metabolic syndrome.  
Accordingly, the goal of this investigation was to examine the hypothesis that 
impaired functional expression of coronary microvascular BKCa channels in metabolic 
syndrome (16; 108) significantly attenuates the balance between myocardial oxygen 
delivery and metabolism at rest and during exercise-induced increases in MVO2. Studies 
were conducted in conscious, chronically instrumented Ossabaw swine fed a normal 
maintenance diet (11% kcal from fat) or an excess calorie atherogenic diet (45% kcal 
from fat, 2% cholesterol, 20% kcal from fructose) that induces many common features of 
metabolic syndrome, including: obesity, insulin resistance, impaired glucose tolerance, 
and dyslipidemia (16; 22; 49; 145). Data were recorded and arterial and coronary 
venous blood samples collected before and after blockade of BKCa channels with 
penitrem A (10 µg/kg, iv) under baseline/resting conditions and during graded treadmill 
exercise up to ~75% of maximum whole body VO2 (heart rate > 200/min).  
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Methods 
Swine Model of Metabolic Syndrome  
All experimental procedures and protocols used in this investigation were approved by 
the Institutional Animal Care and Use Committee in accordance with the Guide for the 
Care and Use of Laboratory Animals. Lean control swine were fed ~2200 kcal/day of 
standard chow (5L80, Purina, Richmond, IN) containing 18% kcal from protein, 71% kcal 
from complex carbohydrates, and 11% kcal from fat. Metabolic syndrome swine were 
fed an excess ~8000 kcal/day high fat/fructose, atherogenic diet containing 17% kcal 
from protein, 20% kcal from complex carbohydrates, 20% kcal from fructose, and 43% 
kcal from fat (mixture of lard, hydrogenated soybean oil, and hydrogenated coconut oil), 
and supplemented with 2.0% cholesterol and 0.7% sodium cholate by weight (H46T-
F20-5L80, Purina, Richmond, IN). Both lean and metabolic syndrome swine were fed 
their respective diets for 20 weeks. 
 
Surgical Instrumentation and Intravascular Ultrasound 
Ossabaw swine were fasted overnight prior to surgery. The animals were initially 
sedated with telazol (5 mg/kg, sc) and xylazine (2.2 mg/kg, sc). After endotracheal 
intubation, a surgical plane of anesthesia was maintained by mechanical ventilation with 
1 – 3% isoflurane gas with supplemental oxygen. Utilizing sterile technique, a 7F 
vascular introducer sheath (Boston Scientific) was inserted into the right femoral artery 
and a guiding catheter (Amplatz L, sizes 0.75 – 2.0, Boston Scientific) was advanced to 
engage the left main coronary ostium. A 3.2F, 30-MHz Intravascular Ultrasound (IVUS) 
catheter (Boston Scientific) was advanced over a guide wire and positioned in the 
coronary artery. Automated IVUS pullbacks were performed at 0.5 mm/s to obtain artery 
diameters. Video images were analyzed off-line (Sonos Intravascular Imaging System, 
Hewlett Packard) (51). 
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Following the IVUS procedure, a left lateral thoracotomy was performed in the 
fifth intercostal space. A catheter (17 Ga. Pressure monitoring catheter, Edwards 
LifeSciences) was implanted in the descending thoracic aorta to measure aortic blood 
pressure and to obtain arterial blood samples. A second catheter was placed in the 
coronary interventricular vein for coronary venous blood sampling and intravenous drug 
infusions. The left anterior descending coronary artery was dissected free and a 
Transonics perivascular flow transducer was placed around the artery. A chest tube was 
placed to evacuate the pneumothorax and the chest was closed in layers. The catheters 
and the flow transducer wire were tunneled subcutaneously and exteriorized between 
the scapulae. Antibiotics (cephalexin) and aspirin (81 mg) were administered twice daily 
for 7 days. A jacket was placed on the animals to protect the catheters and the flow 
transducer wire. An elastomeric balloon pump (Access Technologies) was connected to 
the coronary venous catheter so heparinized saline (5 U/ml) could be continuously 
infused at 0.5 ml/hr. The aortic catheter was flushed daily and filled with heparinized 
saline (5,000 U/ml) (140; 141; 173). 
 
Experimental Protocol 
Following recovery from surgery, experiments were conducted in lean (n = 6) and 
metabolic syndrome (n = 5) Ossabaw swine before and after inhibition of BKCa channels 
with penitrem A (10 µg/kg, iv) under baseline/resting conditions and during graded 
treadmill exercise up to ~75% of maximum whole body VO2 (heart rate > 200/min). We 
previously demonstrated that this intravenous dose of penitrem A essentially abolished 
coronary vasodilation to the BKCa channel agonist NS1619 in anesthetized, open-chest 
lean Ossabaw swine (16). Coronary blood flow, aortic pressure, and heart rate were 
continuously recorded while the pigs were resting upright on the treadmill and then 
during two levels of treadmill exercise: 1) ~2 mph – 0% grade and 2) ~4 mph – 5% 
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grade. Both lean and metabolic syndrome swine exercised at similar levels. Arterial and 
coronary venous blood samples were collected simultaneously in heparinized syringes 
when hemodynamic variables were stable at rest and at each level of exercise. Each 
exercise period was ~2 min in duration, and the animals were allowed to rest sufficiently 
between each level for hemodynamic variables to return to baseline. 
 
Blood Sampling 
Arterial and coronary venous blood samples were collected, immediately sealed and 
placed on ice. The samples were analyzed in duplicate for pH, PCO2, PO2, glucose, 
hematrocrit, and oxygen content with an Instrumentation Laboratories automatic blood 
gas analyzer (GEM Premier 3000) and CO-oximeter (682) systems. Coronary blood flow 
was normalized to an estimated weight of the LAD perfusion territory as previously 
described by Feigl (55). Myocardial oxygen consumption (MVO2, µl O2/min/g) was 
calculated by multiplying coronary blood flow by the coronary arterial-venous difference 
in oxygen content. Lactate uptake (µmol/min/g) was calculated by multiplying coronary 
blood flow by the coronary arterial-venous difference in lactate concentration.  
 
Statistical Analyses 
Data are presented as mean ± SE. Statistical comparisons were made with t-tests and 
three-way repeated measures analysis of variance (ANOVA) (Factor A: Diet; Factor B: 
Drug Treatment; Factor C: Exercise Level) as appropriate. In all statistical tests, P < 0.05 
was considered statistically significant. When significance was found with ANOVA, a 
Student-Newman-Keuls multiple comparison test was performed to identify differences 
between groups and treatment levels. Linear regression analysis was used to compare 
slopes of response variables (aortic pressure, heart rate, coronary venous PO2, lactate 
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uptake) plotted vs. MVO2. If the slopes of the regression lines were not significantly 
different, an analysis of covariance (ANCOVA) was used to adjust response variables for 
linear dependence on MVO2. 
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Results 
Phenotype of Ossabaw Swine  
Phenotypic characteristics of lean and metabolic syndrome swine are given in Table 3.1. 
We found that 20 weeks of an excess calorie atherogenic diet induced classic features 
of metabolic syndrome in Ossabaw swine. In particular, relative to their lean 
counterparts Metabolic syndrome swine exhibited a 1.3-fold increase in body weight, 
1.4-fold increase in fasting glucose, 3.1-fold increase in fasting insulin, 6.5-fold increase 
in total cholesterol and a 3-fold increase in triglyceride levels. Resting mean aortic 
pressure was not different between lean and metabolic syndrome swine (Table 3.2). 
Metabolic syndrome induced a 4-fold increase in coronary atherosclerosis wall coverage 
of the LAD as well as a non-flow limiting but significant 3-fold increase in percent 
stenosis relative to lean (Figure 3.1). Using the homeostatic model assessment method, 
percent β-cell function and percent increased from 182.6% in lean swine to 217.6% in 
swine with metabolic syndrome likely as compensation for the diminished reduction in 
percent insulin sensitivity from 82.6% in lean to 25.5% in metabolic syndrome swine. 
Meanwhile, insulin resistance increased from 1.2 in lean to 3.9 in metabolic syndrome 
swine. 
Table 3.1 Phenotypic Characteristics of Lean and Metabolic syndrome 
Ossabaw Swine 
 Lean 
Metabolic 
syndrome 
Body Weight (kg) 58 ± 6 77 ± 5* 
Heart wt. / Body wt. * 100 0.41 ± 0.01 0.39 ± 0.05 
Fasting glucose (mg/dl) 71 ± 4 96 ± 7* 
Fasting insulin (ng/dl) 10 ± 1 31 ± 4* 
Total cholesterol (mg/dl) 59 ± 4 383 ± 44* 
LDL/HDL ratio 0.8 ± 0.1 3.4 ± 0.4* 
Triglycerides (mg/dl) 22 ± 2 67 ± 6* 
Values are mean ± SE for lean (n = 6) and metabolic syndrome (n = 5) 
swine. * P<0.05 vs. lean. 
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Table 3.2 Hemodynamic and blood gas variables at rest and during graded treadmill exercise 
in lean and metabolic syndrome Ossabaw swine with and without penitrem A (10 µg/kg, iv). 
  Exercise  
 Rest  Level 1 Level 2 
Systolic Blood Pressure (mmHg)    
Lean 101 ± 7 109 ± 7 119 ± 8* 
Lean + Penitrem A 108 ± 8 107 ± 8 118 ± 9* 
Metabolic syndrome 108 ± 9 114 ± 7   141 ± 5*† 
Metabolic syndrome + Penitrem 109 ± 8   134 ± 11* 148 ± 9* 
    
Diastolic Blood Pressure (mmHg)    
Lean 64 ± 4 67 ± 5 74 ± 6 
Lean + Penitrem A 71 ± 5 68 ± 6 73 ± 7 
Metabolic syndrome 70 ± 8  79 ± 10      92 ± 10*† 
Metabolic syndrome + Penitrem 73 ± 6  90 ± 8*  97 ± 8* 
    
Mean Aortic Pressure (mmHg)    
Lean 84 ± 5 88 ± 6 97 ± 6 
Lean + Penitrem A 90 ± 6 88 ± 7 96 ± 7 
Metabolic syndrome 90 ± 8 97 ± 8    117 ± 7*† 
Metabolic syndrome + Penitrem 92 ± 7 112 ± 9*  122 ± 8* 
    
Heart Rate (beats/min)    
Lean 105 ± 7 169 ± 14* 207 ± 10* 
Lean + Penitrem A 113 ± 8 178 ± 6* 218 ± 9* 
Metabolic syndrome 118 ± 9 178 ± 11* 212 ± 18* 
Metabolic syndrome + Penitrem 120 ± 8 187 ± 14* 204 ± 17* 
    
Coronary Blood Flow (ml/min/g)    
Lean 0.86 ± 0.09 1.40 ± 0.20* 1.77 ± 0.19* 
Lean + Penitrem A 0.92 ± 0.13 1.42 ± 0.19* 1.96 ± 0.26* 
Metabolic syndrome 0.97 ± 0.07 1.58 ± 0.15* 1.84 ± 0.10* 
Metabolic syndrome + Penitrem 1.06 ± 0.11 1.83 ± 0.27* 2.17 ± 0.35* 
    
Coronary Conductance (µl/min/g/mmHg)   
Lean 10.3 ± 1.1 16.1 ± 2.4* 18.5 ± 1.9* 
Lean + Penitrem A 9.9 ± 1.0 16.2 ± 2.1* 20.4 ± 2.2* 
Metabolic syndrome 11.1 ± 1.3 16.8 ± 1.9* 15.8 ± 1.5* 
Metabolic syndrome + Penitrem 11.6 ± 1.4 16.7 ± 2.2* 17.8 ± 2.7* 
    
Myocardial O2 Consumption (µl O2/min/g)   
Lean 103 ± 12 192 ± 39* 240 ± 34* 
Lean + Penitrem A 107 ± 23 182 ± 32* 257 ± 42* 
Metabolic syndrome 108 ± 8 213 ± 31* 253 ± 16* 
 48 
Metabolic syndrome + Penitrem 122 ± 10 243 ± 36* 281 ± 45* 
    
Arterial pH    
Lean 7.55 ± 0.02 7.54 ± 0.01 7.55 ± 0.02 
Lean + Penitrem A 7.54 ± 0.01 7.52 ± 0.03 7.53 ± 0.02 
Metabolic syndrome 7.53 ± 0.01 7.57 ± 0.02 7.54 ± 0.03 
Metabolic syndrome + Penitrem 7.55 ± 0.01 7.55 ± 0.04 7.50 ± 0.05 
    
Arterial PCO2 (mmHg)    
Lean 34 ± 1 33 ± 1 33 ± 1 
Lean + Penitrem A 34 ± 1 34 ± 1 33 ± 1 
Metabolic syndrome 35 ± 1  30 ± 1*  30 ± 2* 
Metabolic syndrome + Penitrem 31 ± 1 32 ± 2 30 ± 2 
    
Arterial PO2 (mmHg)    
Lean 89 ± 3 83 ± 3 84 ± 4 
Lean + Penitrem A 89 ± 4 84 ± 3 77 ± 3 
Metabolic syndrome 83 ± 1    94 ± 2*† 85 ± 4 
Metabolic syndrome + Penitrem 90 ± 3 80 ± 3 82 ± 4 
    
Arterial Hematocrit (%)    
Lean 32 ± 2 37 ± 3 37 ± 2 
Lean + Penitrem A 33 ± 3 35 ± 3 37 ± 3 
Metabolic syndrome 31 ± 3 35 ± 2 34 ± 1 
Metabolic syndrome + Penitrem 30 ± 2 33 ± 3 34 ± 1 
Values are mean ± SE for lean (n = 6) and metabolic syndrome (n = 5) swine. * P < 0.05 
vs. respective baseline (rest); † P < 0.05 vs. lean same level. 
Figure 3.1 Metabolic syndrome 
atherosclerosis is not flow-limiting. 
A: Representative IVUS image of 
Lean LAD demonstrating method of 
determining percent wall coverage. 
B: Representative IVUS image of 
metabolic syndrome LAD 
demonstrating method of 
determining percent stenosis. The 
13% stenosis corresponds to 56% 
wall coverage in this example. C: 
Atherosclerosis is increased in 
metabolic syndrome LAD 
compared to Lean. D: Percent 
stenosis at the site of maximum 
atherosclerosis in the LAD 
demonstrates atherosclerosis in 
metabolic syndrome is not flow-
limiting.  * P < 0.05 vs lean. 
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Effects of Metabolic syndrome on Coronary and Cardiovascular Responses to Exercise 
Hemodynamic and blood gas data at rest and during exercise for the lean and metabolic 
syndrome Ossabaw swine before and after inhibition of BKCa channels are summarized 
in Table 3.2. We found that the exercise-induced increases in blood pressure were 
significantly elevated in metabolic syndrome swine. This effect is also evidenced in the 
relationship between mean aortic pressure and MVO2 shown in Figure 3.2A (P = 0.06). 
No differences in heart rate were noted between groups at rest or during exercise 
(Figure 3.2B). 
 
 
Coronary blood flow and MVO2 were elevated ~2-fold in both lean and metabolic 
syndrome swine at the highest level of exercise. The relationship between coronary 
venous PO2 and MVO2 (Figure 3.3A), a sensitive index of myocardial tissue oxygenation 
that reflects whether changes in myocardial oxygen delivery adequately match increases 
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Figure 3.2  No effect of metabolic syndrome on mean aortic pressure (A) and heart 
rate (B) at rest and during exercise-induced increases in myocardial oxygen 
consumption.  Exercise-induced increases in blood pressure were elevated in 
metabolic syndrome swine as evidenced in the relationship between mean aortic 
pressure and MVO2.  No differences in heart rate were noted between lean or 
metabolic syndrome swine at rest or during exercise. 
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in myocardial metabolism (151), revealed a parallel downward shift in coronary venous 
PO2 at a given level of MVO2 in metabolic syndrome swine (P < 0.001). The impairment 
of myocardial oxygen supply-demand balance in metabolic syndrome swine was 
accompanied by significant decreases in myocardial lactate uptake with exercise-
induced increases in MVO2 (P < 0.005; Figure 3.3B). The net release of lactate across 
the coronary circulation of metabolic syndrome animals, which indicates the onset of 
anaerobic glycolysis and cardiac ischemia, is in stark contrast to the significant 
increases in myocardial lactate uptake (i.e. metabolic consumption) observed during 
exercise in lean animals. 
 
Role of BKCa channels in Local Metabolic Coronary Vasodilation 
Inhibition of BKCa channels with penitrem A (10 µg/kg, iv) did not significantly affect blood 
pressure, heart rate, coronary blood flow or MVO2 in lean or metabolic syndrome swine 
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Figure 3.3  Effect of metabolic syndrome on the relationship between myocardial 
oxygen consumption and coronary venous PO2 (A) and myocardial lactate uptake 
(B).  The relationship between coronary venous PO2 and myocardial oxygen 
consumption revealed a parallel downward shift in coronary venous PO2 at a given 
level of myocardial oxygen consumption in metabolic syndrome swine. This 
impairment of myocardial oxygen supply-demand balance was accompanied by a 
marked release of lactate (negative lactate uptake) in metabolic syndrome swine as 
myocardial oxygen consumption was elevated. 
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at rest or during exercise (Table 3.2). Additionally, Figure 4 demonstrates that the 
relationship between coronary venous PO2 and MVO2 was not significantly affected by 
inhibition of BKCa channels in either lean (Figure 3.4A) or metabolic syndrome (Figure 
3.4B) swine. In fact, administration of penitrem A tended to increase coronary venous 
PO2 at a given level of MVO2, however this effect failed to reach statistical significance (P 
= 0.10). It is important to point out that we previously demonstrated that this intravenous 
dose of penitrem A is effective in inhibiting coronary vasodilation to the BKCa channel 
agonist NS1619 in anesthetized, lean Ossabaw swine (16). Therefore, these data 
indicate that BKCa channels are not required for local metabolic coronary vasodilation 
during exercise.  
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Figure 3.4 Effect of BKCa channel inhibition on the relationship between coronary 
venous PO2 and myocardial oxygen consumption in lean (A) and metabolic 
syndrome (B) swine.  Inhibition of BKCa channels with penitrem A did not 
significantly affect the relationship between coronary venous PO2 and myocardial 
oxygen consumption in either lean or metabolic syndrome swine. 
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Discussion 
Data from this investigation demonstrate that metabolic syndrome significantly 
impairs the ability of the coronary circulation to adequately balance myocardial oxygen 
delivery with myocardial metabolism at rest and during exercise-induced increases in 
MVO2. This supply-demand imbalance forces the myocardium to utilize its limited oxygen 
extraction reserve in effort to meet the tissue requirements for oxygen (Figure 3.3A). The 
marked release of lactate (negative lactate uptake) observed in metabolic syndrome 
swine as MVO2 was elevated indicates that this increase in oxygen extraction was 
inadequate to the extent that myocardial underperfusion and ischemia was evidenced by 
the onset of anaerobic glycolytic metabolism (Figure 3.3B). It is important to recognize 
that the initiation of cardiac ischemia was not related to the presence of a significant flow 
limiting stenosis as metabolic syndrome Ossabaw swine had only ~13% luminal 
narrowing of the coronary circulation (Figure 3.1). These data suggest that coronary 
microvascular dysfunction precipitates the onset of “demand ischemia” as MVO2 is 
elevated in metabolic syndrome hearts that could contribute, at least in part, to the 
increased incidence of myocardial ischemia, infarction and sudden cardiac death 
observed in obese patients with metabolic syndrome (66; 96). Thus, understanding the 
mechanisms responsible the impairment of coronary flow regulation in metabolic 
syndrome is critical to the treatment and possible prevention of these complications. 
The present study was designed to examine the hypothesis that impaired 
functional expression of coronary microvascular BKCa channels (16; 108) significantly 
contributes to the imbalance between myocardial oxygen supply and demand in 
metabolic syndrome. This hypothesis was based on recent data from our laboratory 
which demonstrated impaired membrane trafficking of BKCa channel α and β1 subunits 
in coronary vascular smooth muscle cells from metabolic syndrome Ossabaw swine that 
was accompanied by diminished BKCa channel-mediated current generation and 
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microvascular vasodilation both in vitro and in vivo (16). Given the abundant expression 
of BKCa channels in coronary vascular smooth muscle cells (20; 24; 61; 63; 108; 109) 
and the importance of K+ channels to the regulation of coronary vascular resistance (45; 
47; 156), we predicted that decreases in BKCa channel function would likely contribute to 
diminished local metabolic coronary vasodilation in metabolic syndrome. This assertion 
is supported by a recent study from Merkus et al. who found that administration of the 
BKCa channel inhibitor tetraethylammonium (TEA) resulted in a significant decrease in 
the relationship between coronary venous PO2 and MVO2 in normal-lean swine both at 
rest and during exercise (103). In addition, BKCa channels have also been shown to 
contribute to coronary endothelial-dependent dilation (16; 71; 105; 106) and to the 
regulation of coronary microvascular tone in ischemic dog hearts (115).  
In contrast to our hypothesis we found that the impaired balance between 
myocardial oxygen delivery and MVO2 in metabolic syndrome was not related to the 
diminished contribution of BKCa channels to local metabolic control of coronary blood 
flow. In fact, our data fail to support a functional role for BKCa channels in the regulation 
of coronary microvascular tone at rest or during exercise as the inhibition of BKCa 
channels with penitrem A did not significantly decrease the relationship between 
coronary venous PO2 and MVO2 in lean (Figure 3.4A) or metabolic syndrome (Figure 
3.4B) swine. Although this finding is directly at odds with the early study of Merkus et al. 
(103), it is important to recognize that TEA is also an autonomic ganglionic blocker that 
inhibits sympathetic output (40; 122). Therefore, TEA is a non-selective inhibitor that 
would not only affect the balance between coronary blood flow and MVO2 by inhibiting 
BKCa channels but also by decreasing β-adrenoceptor mediated coronary vasodilation, a 
prominent, well accepted mechanism of exercise-induced coronary vasodilation (44; 54; 
64; 65; 107). In addition, even though BKCa channels are known to contribute to 
adenosine-induced and endothelial (NO)-mediated dilation (16; 71; 105; 106), the lack of 
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an effect of BKCa channel inhibition on myocardial oxygen supply-demand balance is not 
surprising given that numerous earlier studies have failed to establish a role for 
adenosine or NO in exercise-induced coronary vasodilation (6; 14; 46; 78; 142; 152; 
153; 155; 158). Whether increases in the activity of other K+ channels (i.e. KATP and/or 
Kv) compensate to regulate coronary flow when BKCa channels are inhibited is unknown 
and merits further study.  
In summary, our data indicate that factors released from the vascular 
endothelium and/or myocardium do not regulate local metabolic control of coronary 
blood flow through a BKCa channel-dependent mechanism under physiological (lean) or 
pathophysiological (metabolic syndrome) conditions. Thus, diminished functional 
expression of BKCa channels (16; 26; 38; 101; 108) does not significantly contribute to 
the impairment of myocardial oxygen-supply demand balance at rest or during increases 
in MVO2 in metabolic syndrome. However, our findings do not contradict a role for 
decreases in BKCa channel function contributing to coronary endothelial dysfunction that 
is typically observed in obesity, insulin resistance and metabolic syndrome (22; 88).  
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Abstract 
The mechanisms by which the metabolic syndrome impairs control of coronary 
blood flow have not been clearly defined. This study tested the hypothesis that metabolic 
syndrome reduces coronary vasodilation to cardiac ischemia via decreases in the 
relative contribution of specific K+ channels to the reactive hyperemic response. Studies 
were conducted in anesthetized miniature Ossabaw swine fed a normal maintenance 
diet (11% kcal from fat) or an excess calorie atherogenic diet (45% kcal from fat, 2% 
cholesterol, 20% kcal from fructose) for 9 (MetS-9) or 20 (MetS-20) weeks. Ischemic 
vasodilation was determined by the coronary flow response to a 15 sec transient 
coronary occlusion before and after cumulative administration of the BKCa channel 
antagonist penitrem A (10 µg/kg, iv), the KV channel inhibitor 4-aminopyridine (0.3 mM), 
and the KATP channel antagonist glibenclamide (1 mg/kg). We found that the coronary 
reactive hyperemic response was progressively diminished in MetS-9 and MetS-20 
swine. Inhibition of BKCa channels had no effect on the reactive hyperemic response in 
either lean or MetS-20 swine. Subsequent inhibition of KV channels significantly reduced 
the peak hyperemic response and attenuated the overall volume of repayment in lean 
swine. Additional blockade of KATP channels tended to further diminish the peak coronary 
reactive hyperemic response. Inhibition of BKCa, KV and/or KATP channels had no effect 
on the coronary reactive hyperemic response in MetS-20 swine. These data indicate that 
metabolic syndrome reduces coronary vasodilation to cardiac ischemia via decreases in 
the relative contribution of KV channels to the reactive hyperemic response. 
 
Keywords: coronary blood flow, reactive hyperemia, ischemic vasodilation, K+ channels, 
Ossabaw miniature swine 
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Introduction 
Coronary vasodilation in response to myocardial ischemia is an important 
mechanism that acts to maintain adequate oxygen delivery to the myocardium in order 
to mitigate ischemic injury and infarction (117; 133). Although the exact mechanisms of 
ischemic dilation are not completely understood, earlier studies support that the putative 
vasodilator metabolites adenosine and nitric oxide (NO) significantly contribute to this 
response via activation of vascular smooth muscle K+ channels (5; 9; 36; 47; 117). K+ 
channels have been implicated in mediating ischemic dilation via their purported role as 
end-effectors in vascular smooth muscle. Specifically, it is well known that K+ channels 
mediate vasodilation in response to key endothelial and metabolic metabolites, e.g. 
adenosine (36; 47; 78; 93) and NO (16; 36; 105; 106), as these channels determine 
vascular smooth muscle membrane potential and thereby regulate electromechanical 
control of vascular tone (81; 113). This hypothesis is directly supported by previous 
investigations which documented a role for large conductance Ca2+-activated K+ (BKCa) 
channels (115), voltage-gated K+ (KV) channels (36), as well as ATP-dependent K
+ 
(KATP) channels (10; 28; 173) in coronary vasodilation in response to a brief episode of 
myocardial ischemia, i.e. reactive hyperemia. However, the relative contribution of these 
specific K+ channels to ischemic coronary vasodilation has not been delineated. 
Earlier studies have demonstrated that disease states such as obesity and the 
metabolic syndrome significantly impair control of coronary blood flow (27; 39; 90; 137; 
141; 173). In particular, recent evidence indicates that peripheral (forearm, calf) 
vasodilation in response to ischemia is significantly impaired in obese and type II 
diabetic human patients (2; 34; 79). Although coronary flow reserve has been shown to 
be reduced by obesity and metabolic syndrome (27; 33; 87; 92; 137), no study has 
examined the effects of metabolic syndrome on ischemic coronary vasodilation. Based 
on recent data indicating that metabolic syndrome impairs the functional expression of 
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vascular smooth muscle K+ channels (16; 26; 38; 73; 108) we propose that metabolic 
syndrome attenuates coronary reactive hyperemia via alterations in the contribution of 
specific K+ channels to ischemic vasodilation. Examining the mechanisms by which 
metabolic syndrome affects the coronary response to myocardial ischemia stands to 
improve our understanding of the increased incidence of cardiac arrhythmias, infarction 
and sudden cardiac death observed in obese patients with metabolic syndrome (59; 66; 
70; 75; 76; 96; 129). 
The goal of this investigation was to elucidate the relative contribution of specific 
K+ channels to coronary reactive hyperemia. In particular, we tested the hypothesis that 
metabolic syndrome impairs coronary vasodilation to cardiac ischemia via decreases in 
the relative contribution of BKCa, KV, and/or KATP channels to the reactive hyperemic 
response. To examine this hypothesis, experiments were conducted in acute 
anesthetized miniature Ossabaw swine fed a normal maintenance diet (11% kcal from 
fat) or an excess calorie atherogenic diet (45% kcal from fat, 2% cholesterol, 20% kcal 
from fructose) that induces many common features of metabolic syndrome, including: 
obesity, insulin resistance, impaired glucose tolerance, and dyslipidemia (16; 22; 49; 
145). The contribution of K+ channels to ischemic vasodilation was determined by 
assessing the coronary microvascular response to a 15 sec transient occlusion before 
and after the cumulative administration of selective K+ channel antagonist: 1) BKCa 
channel inhibitor penitrem A (10 µg/kg, iv); 2) KV channel inhibitor 4-aminopyridine (0.3 
mM); plus the 3) KATP channel inhibitor glibenclamide (1 mg/kg). 
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Methods 
Swine Model of Metabolic Syndrome  
All experimental procedures and protocols used in this investigation were approved by 
the Institutional Animal Care and Use Committee in accordance with the Guide for the 
Care and Use of Laboratory Animals. Lean control Ossabaw swine were fed ~2200 
kcal/day of standard chow (5L80, Purina TestDiet) containing 18% kcal from protein, 
71% kcal from complex carbohydrates, and 11% kcal from fat. Metabolic syndrome 
Ossabaw swine were fed an excess ~8000 kcal/day high fat/fructose, atherogenic diet 
containing 17% kcal from protein, 20% kcal from complex carbohydrates, 20% kcal from 
fructose, and 43% kcal from fat (mixture of lard, hydrogenated soybean oil, and 
hydrogenated coconut oil), and supplemented with 2.0% cholesterol and 0.7% sodium 
cholate by weight (5B4L, Purina TestDiet). Swine were fed their respective diets for 9 or 
20 weeks. 
 
Surgical Preparation and In Vivo Coronary Blood Flow Studies  
Lean, metabolic syndrome swine following 9-weeks of diet (MetS-9) and metabolic 
syndrome swine following 20-weeks of diet (MetS-20) were sedated with telazol (5 
mg/kg, sc) and xylazine (2.2 mg/kg, sc). Animals were intubated and ventilated with O2-
supplemented air. Anesthesia was maintained with morphine sulfate (3 mg/kg, im) and 
α-chloralose (100 mg/kg, iv). Catheters were placed in the right femoral artery and vein 
as well as the left femoral artery. Blood pressure was measured from the right femoral 
artery catheter. Further, arterial blood was drawn from this catheter to analyze blood 
gases parameters every 15 – 30 min. Ventilatory adjustments and/or sodium 
bicarbonate administration was performed as required to arterial blood gases within 
normal physiological limits. A left thoracotomy was performed at the fifth intercostal 
space. The left lung was restrained in gauze and the pericardium was opened. A 
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proximal portion of the left anterior descending coronary artery (LAD) was isolated and a 
perivascular Transonics flow transducer (2.5 mm) was placed around the artery for 
measurement of coronary blood flow as well as a snare occluder for transient LAD 
occlusion.  
Hemodynamic variables were allowed to stabilize 15 – 30 min before initiation of 
the reactive hyperemia protocol. Following baseline measurements, the LAD was 
clamped using the snare occluder for 15 sec and then released to measure the reactive 
hyperemia. The reactive hyperemia protocol was performed under control conditions (n 
= 7) and in MetS-9 (n = 7) and MetS-20 (n = 7) swine. Additional studies were also 
performed to examine the relative contribution of K+ channels to ischemic coronary 
vasodilation in lean (n = 5) and MetS-20 (n = 5) swine by the cumulative administration 
of 1) BKCa channel antagonist penitrem A (10 µg/kg, iv); 2) KV channel antagonist 4-
aminopyridine (4-AP, 0.3 mM, iv); 3) KATP channel blocker glibenclamide (1 mg/kg, iv). 
Since sulfonylureas stimulate insulin secretion, glibenclamide was prepared in a glucose 
solution. LAD perfusion territory was estimated as previously described by Feigl et al. 
(55). 
 
Statistical Analyses 
Data are presented as mean ± SE from n pigs. Hyperemic volume was calculated as 
area under the curve with Prism software (GraphPad, San Diego, CA). Statistical 
comparisons were made with t-tests and two-way repeated measures analysis of 
variance (ANOVA) (Factor A: Diet; Factor B: Drug Treatment) as appropriate. In all 
statistical tests, P < 0.05 was considered statistically significant. When significance was 
found with ANOVA, a Student-Newman-Keuls multiple comparison test was performed 
to identify differences between groups and treatment levels. 
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Results 
Phenotype of Ossabaw Swine  
Phenotypic characteristics of lean and metabolic syndrome swine are given in Table 4.1. 
No differences in key phenotypic parameters were noted between lean swine at 9 vs. 20 
weeks of diet. Data presented in Table 4.1 are from lean swine following 9 weeks of diet 
(body weight of 20 week lean swine averaged 55 ± 7 kg). As previously documented by 
our laboratory (16; 17; 22; 49), we found that 9 and 20 weeks of an excess calorie 
atherogenic diet induced increases in body weight, fasting glucose, total cholesterol as 
well as triglyceride levels; i.e. classic clinical features of metabolic syndrome. 
Intravascular ultrasound revealed a progressive increase in the amount of coronary 
atherosclerosis with the duration of metabolic syndrome. The elevated fasting glucose 
relative to prior studies from our group is likely due to the use of isoflurane anesthesia. 
 
Table 4.1. Phenotypic Characteristics of Lean and Metabolic syndrome Ossabaw 
Swine 
 Lean MetS-9 MetS-20 
Body Weight (kg) 38 ± 3 54 ± 3* 83 ± 7*† 
Fasting glucose (mg/dl) 60 ± 8 126 ± 7* 129 ± 7* 
Total cholesterol (mg/dl) 61 ± 6 316 ± 42* 503 ± 41*† 
Triglycerides (mg/dl) 21 ± 2 24 ± 3 48 ± 5*† 
Values are mean ± SE for lean-9 weeks of diet (n = 7), metabolic syndrome-9 
weeks of diet (MetS-9; n = 7) and metabolic syndrome-20 weeks of diet (MetS-
20; n = 7) swine. * P<0.05 vs. lean. † P < 0.05 vs. MetS-9. 
 
Effects of Metabolic Syndrome on Coronary Reactive Hyperemia 
The effect of metabolic syndrome on coronary vasodilation in response to a 15 sec 
occlusion was determined in lean (n = 7; 9 weeks diet), MetS-9 (n = 7) and MetS-20 (n = 
7) swine. For all in vivo experiments, blood gas parameters were maintained 
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normal physiological limits throughout the experimental protocol in both lean and 
metabolic syndrome swine (arterial values: pH = 7.43 ± 0.02; PCO2 = 41 ± 1 mmHg; PO2 
= 150 ± 9 mmHg). As depicted in Figure 4.1, we found that the average coronary 
reactive hyperemic response was progressively diminished in MetS-9 and MetS-20 
swine. More specifically, the peak reactive hyperemic response trended downward with 
the duration of metabolic syndrome (Figure 4.1D) and the duration of the response 
(defined as time until return to baseline flow for 5 sec) was significantly reduced in 
metabolic syndrome-20 vs. lean swine (Figure 4.1E). The repayment to debt ratio was 
also significantly reduced in both MetS-9 and MetS-20 swine (Figure 4.1F). 
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Figure 4.1 Coronary reactive hyperemia and progression of metabolic syndrome.  
Group average traces of the coronary reactive hyperemia response in lean (A, n = 
7), 9 week-fed metabolic syndrome (B, n = 7) and 20 week-fed Metabolic syndrome 
(C, n = 7) swine.  The peak hyperemic response (D) tended to decrease with the 
degree of metabolic syndrome. The duration (E) of reactive hyperemic response 
was significantly attenuated in MetS-20 swine.  The repayment to debt ratio (F) was 
reduced in both MetS-9 and MetS-20 swine. *P < 0.05 vs. lean-control swine. 
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Table 4.2 Effect of K+ Channel Blockade on Baseline Systemic Hemodynamics & 
Coronary Blood Flow 
Groups 
Mean 
Arterial 
Pressure 
(mmHg) 
Heart 
Rate 
(bpm) 
Coronary 
Blood Flow 
(ml/min/g) 
Coronary 
Conductance 
(µl/min/g/mmHg) 
Lean 
Lean + PenA 
Lean + PenA + 4AP 
Lean + PenA + 4AP + Glib 
 
MetS-20 
MetS-20 + PenA 
MetS-20 + PenA + 4AP 
MetS-20 + PenA + 4AP + Glib 
99 ± 8 
101 ± 6 
   131 ± 11* 
 144 ± 7* 
 
90 ± 5 
90 ± 3 
106 ± 6* 
122 ± 6* 
66 ± 10 
64 ± 12 
49 ± 8* 
49 ± 8* 
 
68 ± 6 
65 ± 9 
55 ± 2 
58 ± 2 
0.52 ± 0.08 
0.55 ± 0.12 
0.56 ± 0.10 
0.47 ± 0.10 
 
0.60 ± 0.04 
0.70 ± 0.04 
0.78 ± 0.07 
0.69 ± 0.07 
5.3 ± 0.5 
5.1 ± 0.8 
 3.9 ± 0.7* 
 3.1 ± 0.6* 
 
6.7 ± 0.4 
7.6 ± 0.5 
7.2 ± 0.8 
5.7 ± 0.5 
Values are mean ± SE for lean 20-weeks of diet (n = 5) and 20-week Metabolic 
syndrome (MetS-20; n = 5) swine. Pen A = penitrem A; 4-AP = 4-aminopyridine; Glib = 
glibenclamide. * P < 0.05 vs. respective untreated control. 
 
Effect of K+ Channel Blockade on Baseline Hemodynamics and Coronary Blood Flow 
To investigate the relative contribution of BKCa, KV, and KATP channels to ischemic 
coronary vasodilation, experiments were conducted in MetS-20 and aged matched lean 
(20 weeks of diet) swine before and after cumulative administration of specific K+ 
channel blockers. Table 4.2 illustrates the effect of intravenous infusion of these K+ 
channel blockers on baseline systemic hemodynamic and coronary blood flow. Inhibition 
of BKCa channels with penitrem A (10 µg/kg) did not significantly affect mean aortic 
pressure, heart rate or coronary blood flow in lean or MetS-20 swine. Subsequent 
administration of the KV channel antagonist 4-AP (0.3 mM) markedly increased blood 
pressure > 30 mmHg in lean swine, and 16 mmHg in MetS-20 swine, which resulted in a 
reflex-mediated decrease in heart rate. Successive addition of the KATP channel 
antagonist glibenclamide (1 mg/kg) caused a further elevation of blood pressure in both 
lean and MetS-20 swine. Baseline coronary blood flow was not significantly altered by K+ 
channel inhibition in either group. This lack of an effect on coronary flow was directly 
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related to the marked elevation in arterial pressure as normalization of coronary blood 
flow to aortic pressure revealed a significant reduction in coronary conductance following 
administration of 4-AP and glibenclamide. However, this effect of K+ channel blockade 
was only observed in lean swine.  
 
Contribution of K+ Channels to Coronary Reactive Hyperemia 
The effect of K+ channel inhibition on the coronary reactive hyperemic response is 
shown in Figure 4.2 for lean swine and in Figure 4.3 for MetS-20 swine. Given the 
marked increases in mean aortic pressure following administration of 4-AP and 
glibenclamide (Table 4.2), coronary conductance data were used to assess the relative 
contribution of K+ channels to ischemic coronary vasodilation. We found that blockade of 
BKCa channels with penitrem A had no effect on the reactive hyperemic response in 
either lean (Figures 4.2A, 4.2D, and 4.2E) or MetS-20 (Figures 4.3A, 4.3D, and 4.3E) 
swine. Consistent with our recent findings (36), subsequent inhibition of Kv channels with 
4-AP reduced the peak hyperemic response (Figure 4.2D; P = 0.07) and significantly 
decreased the overall volume of repayment (Figure 4.2E) in lean swine. Additional 
blockade of KATP channels tended to further diminish (~15%) the peak coronary reactive 
hyperemic response (P = 0.08). Combined inhibition of BKCa, KV and KATP channels 
significantly diminished the degree of coronary reactive hyperemia, i.e. the volume of 
repayment was reduced ~50% in lean swine (Figure 4.2E). In contrast, inhibition K+ 
channels alone or in combination had no effect on the coronary reactive hyperemic 
response in MetS-20 swine (Figure 4.3A-E).  
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Figure 4.3 Effect of K+ channel inhibition on coronary reactive hyperemia in metabolic 
syndrome swine (n = 5).  The average control reactive hyperemia response is plotted 
(black line) relative to the cumulative administration of the BKCa channel antagonist 
penitrem A (A; Pen A), the KV channel antagonist 4-aminopyridine (B; 4-AP), and the KATP 
channel antagonist glibenclamide (C; Glib) (K+ channel blockade shown by dashed grey 
line). K+ channel inhibition had no effect on the peak hyperemic conductance (D) or the 
volume of repayment (E) relative to baseline control.  
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Figure 4.2  Effect of K+ channel inhibition on coronary reactive hyperemia in lean swine 
(n = 5).  The average control reactive hyperemia response is plotted (black line) relative 
to the cumulative administration of the BKCa channel antagonist penitrem A (A; Pen A), 
the KV channel antagonist 4-aminopyridine (B; 4-AP), and the KATP channel antagonist 
glibenclamide (C; Glib) (K+ channel blockade shown by dashed grey line). Peak 
hyperemic conductance (D) and the volume of repayment (E) were diminished following 
the administration of 4-AP and Glib. *P < 0.05 vs. control; † P = 0.07 vs. control. 
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Discussion 
The present investigation was designed to elucidate the relative contribution of 
K+ channels to coronary reactive hyperemia in lean and metabolic syndrome Ossabaw 
swine. In particular, we tested the hypothesis that metabolic syndrome impairs coronary 
vasodilation to cardiac ischemia via decreases in the relative contribution of BKCa, KV, 
and/or KATP channels to the reactive hyperemic response. The primary findings of this 
study are: 1) Coronary reactive hyperemia is progressively diminished in relation to the 
duration and degree of metabolic syndrome; 2) BKCa channels do not contribute to the 
reactive hyperemic response in lean or metabolic syndrome swine; 3) KV channels 
significantly contribute to ischemic coronary vasodilation in lean but not metabolic 
syndrome swine; and 4) KATP channels play a modest role in the coronary reactive 
hyperemic response in the presence of BKCa and KV channel inhibition in lean swine. 
Taken together, these data indicate that the metabolic syndrome significantly impairs 
coronary vasodilation to cardiac ischemia via reductions in the relative contribution of KV 
channels to the dilator response. 
Our data demonstrate that the ability of the coronary circulation to vasodilate in 
response to a brief episode of myocardial ischemia is markedly depressed by induction 
of metabolic syndrome (Figure 4.1). It is important to recognize that this impairment was 
not related to the presence of a significant flow limiting stenosis as we have previously 
demonstrated that similarly-fed metabolic syndrome Ossabaw swine had only ~13% 
luminal narrowing of the coronary circulation (17). Our finding is consistent with earlier 
studies that found decreases in coronary flow reserve (27; 33; 87; 92; 137) and impaired 
ischemic peripheral (forearm, calf) vasodilation (2; 34; 79) in obese human patients. In 
addition, these data nicely extend our earlier observation of impaired metabolic control of 
coronary blood flow at rest and during exercise-induced increases in MVO2 (17; 141; 
173). Taken together, these findings importantly establish that coronary microvascular 
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dysfunction in metabolic syndrome impairs the ability of the coronary circulation to 
respond to both physiologic (exercise) and pathophysiologic (ischemia) stimuli.  
We hypothesized that metabolic syndrome impairs coronary reactive hyperemia 
via the diminished contribution of specific K+ channels to the ischemic vasodilatory 
response. This hypothesis is based on earlier studies which documented a role for BKCa 
(115), KV (36), and KATP (10; 28; 172) channels in ischemic vasodilation in normal-lean 
subjects as well as recent data indicating that metabolic syndrome impairs the functional 
expression of these K+ channels in vascular smooth muscle cells (16; 26; 38; 73; 108). 
However, to date no study has examined the relative contribution of K+ channels to the 
coronary reactive hyperemic response in the context of metabolic syndrome. We found 
that BKCa channels do not contribute to the regulation of ischemic vasodilation in either 
lean (Figure 4.2) or MetS-20 (Figure 4.3) swine as BKCa channel inhibition with penitrem 
A (10 µg/kg, iv) had no effect on the peak hyperemic response or the overall volume of 
repayment. These data are in contrast with an earlier study by Node et al. which showed 
that inhibition of BKCa channels with iberiotoxin reduced both the peak coronary reactive 
hyperemic response and the repayment/debt ratio by ~20% in anesthetized dogs (115). 
Aside from differences in species, anesthesia and BKCa channel antagonist used, the 
reason for these discrepant results is unclear. However, it is important to point out that 
we previously demonstrated that the dose of penitrem A used in this study is effective as 
it essentially abolished coronary vasodilation in response to the BKCa channel agonist 
NS1619 in anesthetized, open-chest lean Ossabaw swine (16). Therefore, we are 
confident that BKCa channels play little, if any role in coronary vasodilation at rest or in 
response to cardiac ischemia in lean or metabolic syndrome Ossabaw swine. 
Consistent with a recent study from our laboratory (36), we found that KV 
channels play an important role in the regulation of baseline coronary blood flow and the 
reactive hyperemic response in lean-control swine. This effect was evidenced by the 
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decrease in coronary conductance at rest (Table 4.2) and the reduction of the peak 
hyperemic response and the volume of repayment (Figure 4.2) following the 
administration of the KV channel antagonist 4-AP (0.3 mM) to swine pre-treated with 
penitrem A, i.e. combined blockade of BKCa and KV channels. Since the inhibition of BKCa 
channels alone had no effect on key coronary response variables we attribute these 
changes to 4-AP sensitive KV channels; i.e. not to compensatory increases in KV channel 
activity. This assumption is supported by the previous findings of Dick et al. which 
documented a similar ~35% reduction in volume of repayment (Figure 4.2E) following 
inhibition of KV channels alone (36). We failed to find any evidence for a role of KV 
channels in mediating either baseline coronary flow or the reactive hyperemic response 
in metabolic syndrome-20 swine (Figure 4.3). The decreased contribution of KV channels 
to reactive hyperemia in metabolic syndrome could be related to alterations in channel 
function and/or vasoactive factors and their respective signaling pathways that result in 
the activation of KV channels. Based on recent whole-cell patch-clamp data from our 
laboratory which found no difference in KV channel current in isolated coronary vascular 
smooth muscle cells from lean vs. metabolic syndrome Ossabaw swine (16), we 
propose that the diminished contribution of KV channels is mediated by specific changes 
in channel activation. For example, earlier studies indicate that NO contributes to the 
coronary reactive hyperemic response (5; 9; 36; 47; 117) largely via a KV channel-
dependent pathway (36). Therefore, diminished coronary endothelial NO production, 
which is typically observed in metabolic syndrome (22; 88), would be expected to 
diminish the activation of KV channels and thus their contribution to the overall 
hyperemic response. Alternatively, alterations in the production and/or signaling of the 
cardiac metabolite H2O2 could also play a role (36; 130; 131; 135). Further studies are 
needed to elucidate the exact mechanisms underlying the diminished contribution of KV 
channels to coronary vasodilation in response to cardiac ischemia.  
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Our data do not support a significant role for KATP channels in coronary reactive 
hyperemia, at least in the presence of combined BKCa and KV channel blockade. 
Although, we did find that additional blockade of KATP channels tended to further diminish 
the peak coronary reactive hyperemic response in lean swine (~15%; P = 0.08). Since 
we did not conduct studies with glibenclamide alone and earlier data have shown this 
drug reduces the peak hyperemic response by ~30% in normal dogs (48), we cannot 
exclude a more prominent role for KATP channels in the absence of BKCa and KV channel 
inhibition. However, our data do show that combined inhibition of BKCa, KV and KATP 
channels significantly diminishes the degree of coronary reactive hyperemia, i.e. the 
volume of repayment by ~50% (Figure 4.2E). Therefore, vasoactive mediators that 
converge on these K+ channels, in particular KV channels, comprise a significant 
proportion of the coronary vasodilatory response to ischemia. Furthermore, we submit 
that the lack of an affect of combined K+ channel blockade on the coronary reactive 
hyperemic response in metabolic syndrome swine (Figure 4.3E) indicates that 
diminished contribution of K+ channels to ischemic dilation represents an important 
mechanism of this coronary microvascular dysfunction in metabolic syndrome.  
In summary, findings from this investigation demonstrate that metabolic 
syndrome significantly impairs coronary vasodilation in response to cardiac ischemia. 
The decrease in coronary reactive hyperemia in metabolic syndrome is not related to 
decreases in coronary BKCa channel function (16; 108) but more directly to a diminished 
contribution of KV channels to the ischemic dilator response. We propose that this 
decrease in the functional contribution of KV channels to the control of coronary blood 
flow in metabolic syndrome likely represents a critical mechanism underlying the 
increased incidence of cardiac arrhythmias, infarction and sudden cardiac death in 
obese patients with the metabolic syndrome that should be further explored (59; 66; 70; 
75; 76; 96; 129).  
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CHAPTER 5: DISCUSSION 
 
Major findings of this investigation 
Earlier studies have demonstrated that coronary microvascular function is 
markedly impaired by the onset of metabolic syndrome (27; 39; 90; 137; 141; 173) and 
indicate that this may be an important contributor to increased cardiovascular events in 
obese patients with this combined disorder (59; 66; 70; 75; 76; 96; 129). There is 
mounting evidence that implicate coronary K+ channel dysfunction in metabolic 
syndrome as key mechanisms underlying the deleterious effects of metabolic syndrome. 
Recent investigations have identified impaired BKCa channel activity in coronary 
microvascular smooth muscle of alloxan-diabetic dyslipidemic swine (108), mesenteric 
microvessels of insulin resistant rats (38), and coronary arterial myocytes of diabetic 
fatty rats (26; 101). In addition, BKCa channels are highly expressed in the coronary 
vascular smooth muscle cells (20; 108; 143) and have been implicated as end-effectors 
in the regulation of coronary vasodilation in response to key endothelial and metabolic 
metabolites (71; 105; 106). However, the contribution of BKCa channel defects to the 
control of coronary blood flow and vascular dysfunction in metabolic syndrome has not 
been examined. Further, although studies have shown that BKCa channels contribute to 
coronary endothelial-dependent and exercise-induced dilation under normal-lean 
conditions (16; 103; 105; 106), no study has examined the contribution of BKCa channels 
to metabolic coronary vasodilation in the setting of metabolic syndrome. Recent 
literature also documented a role for BKCa channels (115), KV channels (36), as well as 
KATP channels (10; 28; 172) in coronary vasodilation in response to a brief episode of 
myocardial ischemia, i.e. reactive hyperemia. Yet, the relative contribution of these 
specific K+ channels to ischemic coronary vasodilation has not been delineated in lean 
or obese subjects with metabolic syndrome. Accordingly, the purpose of this 
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investigation was to examine the contribution of K+ channels to coronary vascular 
disease in metabolic syndrome. The major findings of this investigation are as follows: 
1) Coronary microvascular dysfunction in metabolic syndrome significantly 
impairs coronary vasodilation in response to metabolic and ischemic stimuli. Our 
data showed that the metabolic syndrome significantly depressed the relationship 
between coronary venous PO2 and MVO2 at rest and during exercise. Furthermore, we 
found a marked release of lactate (negative lactate uptake) in metabolic syndrome swine 
during exercise which indicates an imbalance between myocardial oxygen delivery and 
consumption to the point of overt cardiac ischemia. In additional studies we 
demonstrated that the ability of the coronary circulation to vasodilate in response to a 
brief episode of myocardial ischemia is progressively diminished in relation to the 
duration and degree of metabolic syndrome. This effect was evidenced by a decrease in 
the coronary reactive hyperemia repayment to debt ratio. It is important to recognize that 
the impairment of coronary vasodilation in response to both physiologic (exercise) and 
pathophysiologic (ischemia) stimuli was not related to the presence of a significant flow 
limiting stenosis; i.e. the impaired responses are directly related to coronary 
microvascular dysfunction and not the presence of significant atherosclerotic disease. 
We propose that the impairment of coronary microvascular function could contribute to 
the greater incidence of arrhythmias, sudden cardiac death, and other cardiovascular-
related events exhibited in metabolic syndrome. 
2) Coronary microvascular dysfunction in metabolic syndrome is related to 
decreased membrane trafficking and functional expression of BKCa channels that 
is accompanied by significant increases in L-type Ca2+ channel-mediated coronary 
vasoconstriction and increased intracellular Ca2+ concentration. Experiments 
revealed that coronary vasodilation in response to BKCa channel activation was 
attenuated in metabolic syndrome swine that was related to diminished current and 
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reduced membrane trafficking of these channels. Despite this, we found that BKCa 
channels do not significantly contribute to coronary vasodilation in response to local 
metabolic (exercise) or ischemic stimuli. We did however observe that inhibition of BKCa 
channels diminished coronary vasodilation to bradykinin in anesthetized open-chest lean 
Ossabaw swine, thus indicating BKCa channel involvement in endothelial-dependent. 
This observation is consistent with our isometric tension studies on freshly isolated 
circumflex coronary arteries (Figure 5.1) which showed significant attenuation of 
endothelial-dependent vasodilation to bradykinin in metabolic syndrome swine (EC50 
10.0 ± 1.3 nM) relative to lean (EC50 0.8 ± 0.8 nM). Furthermore, endothelial-
independent dilation to sodium nitroprusside was significantly increased in arteries from 
metabolic syndrome (EC50 0.4 ± 1.2 µM) compared to lean (EC50 2.9 ± 1.0 nM) swine. 
These data suggest that metabolic syndrome-induced coronary endothelial dysfunction 
is accompanied by a heightened response to NO in vascular smooth muscle, consistent 
with hypersensitivity of vascular smooth muscle to NO previously documented by 
Moncada et al. (110). However, at present we have not examined the extent to which 
BKCa channel dysfunction contributes to coronary microvascular endothelial dysfunction 
in metabolic syndrome. Based on these studies we hypothesize that alterations in 
electromechanical coupling contribute to coronary endothelial dysfunction (71; 105; 106) 
and the sensitization of key vasoconstrictor pathways (39; 88; 90; 141; 173) typically 
observed in obese subjects with metabolic syndrome.  
Although we did not uncover a functional role for BKCa channels in exercise or 
ischemic dilation, the abundance of coronary vascular smooth muscle BKCa channels 
((20)) and their capacity to be activated strongly suggest a role for these channels in 
mediating vascular tone. Numerous endogenous modulators of vascular BKCa channels 
have been identified. Putative EDHFs such as epoxyeicosatrienoic and 
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dihydroxyeicosatrienoic acids (97) as well as hydrogen peroxide (104) and shear stress 
(106) have been implicated in flow-induced vasodilation. BKCa channels are also 
regulated by kinase activity, in particular cyclic AMP- and cyclic GMP-dependent protein 
kinases, as activation of these kinases resulted in stimulation of rat cerebral artery 
smooth muscle BKCa channels (163). Other modulators such as endocannabinoids (62) 
and estrogenic compounds (35; 37) have also been identified as activators of BKCa 
channels. 
In contrast, known endogenous inhibitory modulators of BKCa channels include 
ROS (147) and angiotensin II (126, 93). BKCa channel activity has also been found to be 
affected by membrane cholesterol. Cholesterol is necessary for proper BKCa channel 
function as they reside in lipid rafts for optimal function. However, the affect of high 
cholesterol on BKCa channels is still unknown as hypercholesterolemia has been shown 
to both impair BKCa channel activation by impairing signaling of factors that activate 
these channels (62) and by impeding BKCa channel subunit trafficking to the membrane 
(83), whereas other studies have demonstrated increased BKCa channel current in the 
presence of high cholesterol (109). Further studies are needed to elucidate the effects of 
cholesterol on BKCa channel activity. 
Figure 5.1 Metabolic syndrome markedly impaired coronary endothelial function 
in coronary arteries from Ossabaw swine (A).  This was accompanied by a 
vascular smooth muscle hypersensitivity to NO (B). 
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Little is known about modulation of vascular smooth muscle BKCa channels by 
perivascular adipose, neural signaling, or platelet products. Given the abundant 
expression and diversity of smooth muscle BKCa channel tetramers, these various 
modulators likely permit site specific regulation of vascular tone that may be useful as 
therapeutic targets. More research is needed, however, to elucidate the functional role of 
BKCa channel in the regulation of vascular resistance. 
3) Metabolic syndrome significantly impairs coronary microvascular 
vasodilation to cardiac ischemia via reductions in the relative contribution of KV 
channels to the dilator response. Consistent with a recent study from our laboratory 
(36), we found that KV channels play an important role in the regulation of baseline 
coronary blood flow and the reactive hyperemic response in lean-control swine. This 
effect was evidenced by a decrease in coronary conductance at rest and a reduction of 
the peak hyperemic response and the volume of 
repayment following the administration of the KV 
channel antagonist 4-AP. We failed to find any 
evidence for a role of KV channels in mediating 
either baseline coronary flow or the reactive 
hyperemic response in the setting of metabolic 
syndrome. Given that our whole-cell patch clamp 
data did not show any evidence for altered KV 
channel function in vascular smooth muscle cells from 
swine with metabolic syndrome (Figure 5.2), we 
purpose that the loss of KV channel involvement in 
ischemic vasodilation is not due to altered channel 
function, but rather due to alterations in factors that 
Figure 5.2 KV channel 
current in coronary artery 
smooth muscle cells from 
lean (open circle) vs. 
metabolic syndrome (closed 
circle) Ossabaw swine in the 
presence of penitrem A.  
 77 
activate the channel. We submit that this decrease in the functional contribution of KV 
channels to the control of coronary blood flow in metabolic syndrome likely represents a 
critical mechanism underlying the increased incidence of cardiac arrhythmias, infarction 
and sudden cardiac death in obese patients with metabolic syndrome that should be 
further explored (59; 66; 70; 75; 76; 96; 129). 
 
 
 
 
 
 
 
 
 
 
Future directions 
Mechanisms of BKCa Channel Trafficking  
Findings from this investigation indicate that coronary vascular endothelial 
dysfunction in metabolic syndrome is related, at least in part, to diminished functional 
expression of vascular smooth muscle BKCa channels via impaired membrane trafficking. 
However, the mechanisms underlying BKCa channel trafficking remain unknown. One 
Figure 5.3 Schematic 
diagram of the 
contribution of K+ 
channels to coronary 
microvascular 
dysfunction in 
metabolic syndrome.  
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possibility is alternative mRNA splicing that yields BKCa channels that are not trafficked 
to the cell membrane. Alternative splicing refers to the generation of several different 
mature mRNA transcript isoforms from a single gene due to variations in the splicing 
reaction of pre-mRNA, the primary gene transcript. The inclusion of exclusion of exons in 
the final product, or the recognition of different splice sites by the spliceosome that 
carries out the reaction, can alter the resultant final mRNA transcript. This phenomenon 
allows for a greater diversity of protein products to be generated from a single gene. The 
BKCa channel is comprised of a tetramer of pore-forming α subunits encoded by the 
single KCNMA1 (aka Slo1) gene. This gene is highly alternatively spliced, and it is the 
assembly of these channel variants that yield functional BKCa channels with different 
properties despite its ubiquitous expression throughout various tissues in the body. 
Alternative mRNA splicing has been linked to alterations in cell surface expression. For 
example, alternative splicing that skips exon 23 are dominant-negative for surface 
expression and when combined with other a subunits, prevents membrane, but not total, 
BKCa channel expression as these channels are trapped intracellularly (30). Motifs in the 
large cytoplasmic C-terminal are particularly important in determining the functional 
properties of BKCa channels, and alternative splicing in these sites can drastically alter 
expression on the plasma membrane (86; 95). An N-terminal insert has also been 
identified that prevents membrane trafficking of BKCa α-subunits and leads to 
intracellular accumulation of the channels (170; 171). 
Yet another possibility is formation of BKCa channels with accessory subunits that 
inhibit membrane expression. In addition to modulation Ca2+/voltage sensitivity and the 
biophysical and pharmacological properties of BKCa channels, the accessory β1-subunit 
has recently been shown to alter channel trafficking. Toro et al. has found that β1-subunit 
decreases the surface expression of BKCa channels via an endocytic targeting 
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mechanism (149). This suggests that increases in β1 subunit expression could reduce 
the functional expression of BKCa channels at the membrane.  
 
Diminished BKCa channel activity 
Alternative splicing can also produce channels with reduced Ca2+- and/or 
voltage-sensitivity. Alterations in the major exon that affects Ca2+/voltage-sensitivity of 
BKCa α-subunits, in particular the STREX exon, can influence membrane expression and 
reduction of this key exon was found to produce a phenotype of functional impairment 
(167) regardless of increased total BKCa channel expression (166). Further, BKCa 
channel sensitivity to Ca2+ has been found to be significantly enhanced by the tissue-
specific expression of auxiliary β1 subunit (11). The BKCa channel β1 subunit also 
amplifies the functional effects of α-subunit oxidation leading to increase in channel open 
probability and slowed channel deactivation (136). Further, this enhanced sensitivity of 
BKCa channels due to the accessory β1 subunit could be diminished in disease. 
Sensitivity to Ca2+ was diminished in hypercholesterolemia that was related to reduced 
BKCa channel β1 subunit expression in rabbit sphincter of Oddi (136). Thus a reduction in 
the Ca2+/voltage-sensitivity of BKCa channels could decrease current generated at a 
given voltage and Ca2+ concentration, simultaneous with an increase in total BKCa 
channel protein expression. 
 
KV Channels in Metabolic Syndrome 
Ours was the first investigation to examine the contribution of KV channels to the 
coronary reactive hyperemic response in the context of metabolic syndrome. As outlined 
above, we propose that the diminished contribution of KV channels to coronary ischemic 
vasodilation is mediated by specific changes in channel activation and not changes in 
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channel activity per se (see Figure 5.2 above). For example, earlier studies indicate that 
NO contributes to the coronary reactive hyperemic response (136) largely via a KV 
channel-dependent pathway (36). Therefore, diminished coronary endothelial NO 
production, which is typically observed in metabolic syndrome (22; 88), would be 
expected to diminish the activation of KV channels and thus their contribution to the 
overall hyperemic response. Alternatively, alterations in the production and/or signaling 
of the cardiac metabolite H2O2 could also play a role (36; 130; 131; 135). Alterations in 
the availability and/or signaling of adenosine, which has been found to be an important 
mediator in hypoxic vasodilation (13) and reactive hyperemia (118; 119; 134), could also 
influence this response. However, we found no change in adenosine dilation in isolated 
coronary arterioles between lean and metabolic syndrome swine. This may be due to the 
fact that these experiments were conducted in 9 week high fat-fed swine and thus 
metabolic syndrome had not progressed enough to obtain significant results.  
Additional studies are also needed to more specifically study coronary vascular 
smooth muscle KV channel function and activity as well as examine possible changes in 
membrane trafficking that could also diminish functional expression of these important 
vasoregulatory channels. Further studies are also needed to elucidate the specific Kv 
channel subtype(s) involved. Our earlier study indicates that KV1 channels serve as end-
effectors that integrate multiple physiological, pathophysiological, and pharmacological 
stimuli to regulate coronary microvascular resistance (36). However, the effect of 
metabolic syndrome on KV1 channels has not been examined. The contribution of other 
KV channel subtypes to the regulation of coronary vascular resistance, especially in the 
context of metabolic syndrome, merits further study.  
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K+ Channel Electromechanical Coupling to L-type Ca2+ Channels  
While K+ channels are critical determinants of membrane potential and 
importantly contribute to the regulation of vasomotor tone, Ca2+ channels also influence 
vascular resistance by controlling levels of intracellular Ca2+ and subsequent activation 
of Ca2+-dependent biochemical machinery. Voltage-gated L-type Ca2+ channels are the 
major source of Ca2+ entry into smooth muscle cells (84; 111). As their activity depends 
on membrane potential set by K+ channels (162), K+ channel impairment, as described in 
this investigation, leads to subsequent depolarization of the smooth muscle and results 
in the opening of L-type Ca2+ channels, increased intracellular Ca2+ levels, and resultant 
vasoconstriction. Consistently, data from this investigation demonstrated that 
vasoconstriction to the L-type Ca2+ channel agonist BayK 8644 was significantly 
elevated in isolated coronary conduit arteries from metabolic syndrome swine relative to 
lean. Further, increased Ca2+ current was reported in cerebrovascular smooth muscle 
cells of high fat-fed rats (159). This suggests that coronary vascular defects of metabolic 
syndrome could be attributed to augmented expression or activity of smooth muscle L-
type Ca2+ channels. More studies are needed to address the function of coronary 
smooth muscle L-type Ca2+ channels in the context of obesity and metabolic syndrome.  
 Recent data from the Sturek laboratory indicates that diabetic dyslipidemia 
increases the functional coupling of BKCa channels to sarcoplasmic reticulum Ca
2+ 
release in vascular smooth muscle cells from large-conduit coronary arteries (108). This 
increase was attributed to a compensatory change in response to the decrease in Ca2+ 
influx from L-type Ca2+ channels and augmented vasoconstrictor influence as previously 
noted in conduit arteries of aldosterone-salt hypertensive rats (99). Several vascular 
complications in diabetes mellitus has been linked to altered regulation of myoplasmic 
Ca2+ (72), including alterations in Ca2+ influx, smooth muscle cell intracellular Ca2+ levels, 
and Ca2+ signaling. Hill et al. previously observed an increase in Ca2+ buffering by the 
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plasma membrane Ca2+ pump and an increase in the activity and expression of 
sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) (72). This is consistent with 
other studies identifying impaired Ca2+ transporter function in diabetes mellitus (91) and 
high glucose (94). However, additional studies in coronary microvessels revealed a 
significant decrease in the coupling of sarcoplasmic reticulum-mediated Ca2+ spark 
events with STOC frequency (108). Meanwhile, data from high fat-fed dogs showed 
augmented functional expression of L-type Ca2+ channels in both arteries and arterioles 
(88). Specifically, Knudson et al. demonstrated increased coronary vasoconstriction to 
the L-type Ca2+ channel agonist BayK 8644 in isolated coronary arterioles, enhanced 
nicardipine-induced coronary vasodilation in vivo, and increased L-type Ca2+ channel 
current under basal conditions and in the presence of BayK 8644 in isolated conduit 
arterial smooth muscle cells (88). Since the density of L-type Ca2+ channel current is 
inversely related to arterial diameter (19), L-type Ca2+ channels may be differentially 
regulated in the macro- versus microcirculation. Thus, further studies are needed to 
examine the functional expression of coronary vascular L-type Ca2+ channels in 
metabolic syndrome. 
 
Closing remarks 
Metabolic syndrome is associated with a state of coronary microvascular 
dysfunction that significantly impairs the ability of the coronary circulation to match 
myocardial oxygen delivery with myocardial metabolism. Recent investigations 
implicated coronary K+ channel dysfunction as an important contributor to increased 
cardiovascular events in patients with metabolic syndrome, but this is the first study to 
demonstrate that metabolic syndrome significantly impairs microvascular function to 
exercise-induced and ischemic vasodilation. Though we failed to find evidence to 
support a role of BKCa channels in mediating these processes, we did find that the 
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functional expression of BKCa channel is depressed in metabolic syndrome and may 
contribute to endothelial dysfunction that is classically associated with this syndrome. 
Further, we demonstrated that impaired ischemic dilation is related at least in part to 
diminished KV channel response to ischemic metabolites. Collectively, these findings 
demonstrate that decreased functional expression of K+ channels could be a critical 
mechanism underlying increased morbidity and mortality to coronary and cardiac events 
in patients with metabolic syndrome. Future studies should examine mechanisms 
underlying metabolic syndrome-induced impairment of BKCa channel membrane 
trafficking as well as alterations in KV and L-type Ca
2+ channels.  
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